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Summary 
The high energy demand of fast and aggressively growing tumor cells is covered by both anaer-
obic and aerobic glycolysis. This results in an intracellular accumulation of mostly acidic meta-
bolic products. Thus, balancing the intracellular pH is demanding for tumor cells, yet crucial for 
their optimal proliferation and survival. The carbonic anhydrases (CA) constitute a family of en-
zymes that catalyse the hydration of carbon dioxide, yielding the bicarbonate ion, which serves 
as the main buffer system in most organisms. CA XII is a membrane-tethered isozyme on sev-
eral types of tumors and an excellent target for nuclear medicine diagnosis and therapy. The 
specific CA XII binding 6A10 Fab (fragment antigen binding) was shown to be of great interest 
as a new carrier molecule for a radioactive nuclide. A suitable radionuclide for therapeutic appli-
cations accompanied with single photon emission computed tomography (SPECT) imaging 
techniques is lutetium-177. In this study, the 177Lu-labelled 6A10 Fab was for the first time evalu-
ated in vitro and in vivo as an agent for local intracavitary radioimmunotherapy (RIT) of glioblas-
tomas. To extend the 6A10 Fab´s application beyond the local treatment in the brain, a systemic 
injection for the detection of CA XII expressing tumors was investigated. For this purpose, this 
study evaluated the automated production of copper-64 for radiolabelling purposes to provide 
64Cu-labelled 6A10 Fab for positron emission tomography (PET) studies. 
 
For therapeutic applications, the protein was conjugated with p-SCN-Bn-CHX-A´´-DTPA at a 
molar chelator-to-protein ratio of 1:0.96 and radiolabelled with lutetium-177 with a specific activi-
ty of 1.5 GBq/mg. Radio-TLC revealed a radiochemical purity of greater than 96%. The radio-
conjugate was analyzed via flow cytometry, confirming the persisting CA XII binding capacity 
after successful modification. The radiochemical stability of the compound was determined to be 
greater than 90% after 72 h of incubation in human cerebrospinal fluid (37 °C), human plasma 
(37 °C) and labelling buffer (room temperature). A mouse xenograft model with CA XII-positive 
glioma cells was used for biodistribution studies, autoradiographic examinations and first in vivo 
imaging experiments. The tumor revealed a moderate uptake of up to 3.1 ± 0.9 %ID/g 6 h post 
injection (p.i.) while significantly high and long-lasting kidney retention (55.6 ± 13.0 %ID/g 48 h 
p.i.) was found. Tumor slices were analyzed autoradiographically and microscopically to confirm 
that regions of high activity uptake also show high cell density and vice versa. Tumors were suc-
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cessfully visualized using planar scintigraphy or SPECT/CT techniques and a tumor-to-
contralateral ratio of 2.4 (5 h p.i.) was measured. 
 
Copper-64 was produced using an automated setup and characterized with respect to its use as 
a radiolabelling nuclide. Nickel-64, which was used as target material, was electrochemically 
deposited with yields of up to 96%, automatically send to a cyclotron, and irradiated with protons 
(2 - 5 h, 11 – 14.5 MeV, 20 - 30 µA), yielding a maximum activity of approx. 5 GBq. In addition to 
copper-64, irradiation by-products were quantified by gamma spectroscopy as 0.03 ± 0.10 At% 
55Co, 0.004 ± 0.014 At% 57Co, and 1.4 ± 3.4 At% 61Co at the end of irradiation. Ion chromatog-
raphy of the dissolved target led to a radiochemical purity of >99% in the final product fraction. 
The copper-64, dissolved in 9 ml HCl, was evaporated to dryness and taken up in 400 µl of 
0.1 M HCl. Optimization of the module rinsing methods lead to molar activities of up to 
133 GBq/µmol. The efficiency of rinsing methods was evaluated by determination of non-
radioactive metal contaminations via ICP-OES while the molar activity was calculated by titration 
of the copper-64 with 1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA).  
For diagnostic purposes, the 6A10 Fab was conjugated with p-NCS-Bn-NODA-GA, radiolabelled 
with copper-64 and used for PET imaging and a biodistribution study in mice. First in vivo exper-
iments of the 64Cu-labelled 6A10 Fab showed a high tumor uptake of up to 6.9 ± 1.6 %ID/g. PET 
analysis revealed a tumor-to-contralateral ratio of 11.8 ± 0.3 (n = 2) 4 h p.i.. 
 
The results of this study showed the high potential of the radiolabelled 6A10 Fab fragment for 
possible therapeutic and diagnostic applications. Radiolabelled with lutetium-177, the protein is 
suitable for the local therapeutic application in the brain since it showed a moderate tumor up-
take, and a good radiochemical stability under physiological conditions. Additionally, it does not 
cross the blood-brain barrier (BBB). Further investigations on an orthotopic animal model to 
generate data closer to the final clinical application would be beneficial to estimate the com-
pound´s distribution after a local application. By radiolabelling the Fab with copper-64, high tu-
mor uptake enabling high resolution PET images was achieved, which encourages further inves-
tigations concerning a future systemic application for diagnostic purposes. The automated pro-
duction of copper-64 resulted in good radioactive yields, moderate molar activities and high radi-
ochemical purity. Reproducibility of the production process still needs to be improved further for 
routine supply of copper-64 with high quality for radiolabelling procedures.  
 
 V 
Zusammenfassung 
Aufgrund ihres schnellen und aggressiven Wachstums benötigen Tumorzellen überdurchschnitt-
lich viel Energie. Dieser Bedarf wird größtenteils über aerobe und anaerobe Glykolyse gedeckt, 
was intrazellulär zur Entstehung von sauren Stoffwechselprodukten führt. Um einer Übersäue-
rung entgegenzuwirken sind Puffermoleküle wie Hydrogencarbonate notwendig, die u.a. von der 
Membran-assoziierten Carboanhydrase XII (CA XII) zur Verfügung gestellt werden. Aus diesem 
Grund ist dieses Enzym auf vielen Arten von Tumorzellen überexprimiert und stellt somit ein 
vielversprechendes Zielmolekül für nuklearmedizinische Ansätze in Diagnostik und Therapie 
dar. Das 6A10 Fab Fragment bindet spezifisch an CA XII, weshalb es als Trägermolekül eines 
radioaktiven Nuklides prädestiniert ist. In dieser Arbeit wurde das Protein mit Lutetium-177 mar-
kiert und durch diverse in-vitro und in-vivo Charakterisierungen auf seine mögliche Eignung für 
die lokale Therapie von Glioblastomen untersucht. Darüber hinaus ist eine diagnostische An-
wendung erstrebenswert, weshalb die automatisierte Produktion des PET-Nuklids Kupfer-64 
etabliert und dieses charakterisiert wurde. Schlussendlich wurde das Fab Fragment mit Kupfer-
64 markiert und damit erste in-vivo Daten mittels PET-Bildgebung generiert.  
 
Das Protein wurde zunächst mit dem Chelator p-SCN-Bn-CHX-A´´-DTPA in einem Verhältnis 
von 1:0,96 gekoppelt und anschließend mit 1,5 GBq 177Lu/mg Fab radiomarkiert. Die radioche-
mische Reinheit von mehr als 96% wurde mittels Dünnschichtchromatographie ermittelt. Der 
Erhalt der Bindungsaffinität des modifizierten Fab Fragments am Zielmolekül CA XII wurde mit-
tels Durchflusszytometrie bestätigt und eine radiochemische Stabilität von über 90% nach 72 h 
Inkubation in verschiedenen Medien (Liquor, Plasma und Markierungspuffer) gefunden. Autora-
diographie-, Biodistributions- und erste Bildgebungsexperimente wurden an Mäusen mit subku-
tanen Tumortransplantaten durchgeführt. Der Tumor zeigte 6 h p.i. eine moderate Aktivitätsauf-
nahme von 3,1 ± 0,9 %ID/g, während signifikant hohe Aktivitätswerte in der Niere gefunden 
wurden, die auch 48 h p.i. noch bei 55,6 ± 13,0 %ID/g lagen. Durch autoradiographische Unter-
suchungen an Tumorschnitten, gefolgt von HE-Färbungen und entsprechender mikroskopischer 
Charakterisierung konnte eine Korrelation zwischen Bereichen mit hoher Aktivitätsakkumulation 
und hoher Zelldichte und vice versa festgestellt werden. Die Verteilung des radioaktiven Konju-
gats konnte außerdem in ersten Bildgebungsexperimenten (planare Szintigraphie und 
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SPECT/CT) visualisiert und ein Tumor-zu-kontralateral Verhältnis von 2,4 (5 h p.i.) bestätigt 
werden. 
 
Im zweiten Teil dieser Arbeit wurde die Konjugation und Radiomarkierung des 6A10 Fabs mit p-
NCS-Bn-NODA-GA und Kupfer-64 angestrebt, um erste Information zum in-vivo Verhalten der 
Verbindung mittels PET-Bildgebung und Biodistribution zu erhalten. Dazu wurde die Herstellung 
des Nuklids unter Verwendung der automatisierten Alceo-Module etabliert und das Produkt hin-
sichtlich seiner Eignung zur Radiomarkierung von Proteinen charakterisiert. Elementares Nickel-
64 wurde mit Ausbeuten über 96% abgeschieden, automatisch im Strahlengang des Zyklotrons 
positioniert und bis zu 5 h lang bei 11,0 – 14,5 MeV und 20 - 30 µA mit Protonen bestrahlt. Aus-
beuten von maximal 5 GBq konnten erzielt werden. Entstandene Nebenprodukte wurden mittels 
Gammaspektroskopie quantifiziert und auf das Ende der Bestrahlung zerfallskorrigiert (0,03 ± 
0,10 At% 55Co, 0,004 ± 0,014 At% 57Co und 1,4 ± 3,4 At% 61Co). Das Nuklidgemisch wurde mit-
tels Ionenchromatographie aufgetrennt, was zu einer radiochemischen Reinheit der 64Cu-
Fraktion von über 99% führte. Nach Volumenreduktion lag das Produkt in 400 µl einer 0,1 M HCl 
vor. Die molare Aktivität des Kupfers, ermittelt durch Titration mit TETA, konnte auf 
133 GBq/µmol angehoben werden, nachdem durch Optimierung der Reinigungsmethodik der 
Anteil an nicht-radioaktiven Metallkontaminationen, quantifiziert mittels ICP-OES Messungen, 
signifikant reduziert wurde. Erste Biodistributionsergebnisse mit dem 64Cu-markiertem 6A10 Fab 
zeigten eine hohe Tumoranreicherung von bis zu 6,9 ± 1,6 %ID/g 5 h p.i.. Die PET-
Quantifizierung ergab 4 h p.i. ein Tumor-zu-kontralateral Verhältnis von 11,8 ± 0,3 (n = 2). 
 
Die ersten in-vivo und in-vitro Charakterisierungen des 6A10 Fab in Hinblick auf zukünftige the-
rapeutische und diagnostische Anwendungen zeigten vielversprechende Ergebnisse. Durch die 
Radiomarkierung mit Lutetium-177 in Hinblick auf die lokale Applikation in das Gehirn, konnte 
eine moderate Tumoranreicherung und eine ausreichende radiochemische Stabilität unter phy-
siologischen Bedingungen im systemisch applizierten Xenograft-Modell nachgewiesen werden. 
Zusätzlich dazu zeigte die mangelnde Anreicherung im Gehirn, dass das Radiokonjugat die Blut-
Hirn-Schranke nicht passiert. Weitere Informationen über das in-vivo Verhalten des Moleküls 
nach der lokalen Applikation können zudem durch die Etablierung eines anwendungsnäheren 
Tiermodells generiert werden. 
 
Die systemische Gabe des 64Cu-markierten Proteins führte zu einer guten Tumoranreicherung 
und ermöglichte hochauflösende PET-Bildgebung, was zu weiteren Studien in Hinblick auf die 
Anwendung des Konjugats im Bereich der Krebsdiagnostik motiviert. Die wissenschaftliche Re-
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levanz dieser ersten Ergebnisse sollte in ausführlichen Biodistributions- und Bildgebungsstudien 
bestätigt werden um das weitere Vorgehen in Richtung der humanen Anwendung zu rechtferti-
gen. Die genutzten Alceo-Module ermöglichen die automatische Produktion von Kupfer-64 in 
guter radioaktiver Ausbeute, moderaten molaren Aktivitäten und hoher radiochemischer Rein-
heit. Die Reproduzierbarkeit des Herstellungsprozesses sollte durch weitere Modifikationen wei-
ter verbessert werden, um die regelmäßige Bereitstellung von Kupfer-64 in hoher Qualität für 
Radiomarkierungszwecke gewährleisten zu können. 
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 1 
1 Nomenclature 
  
%ID/g Percentage injected dose per gram 
Am Molar activity [GBq/µmol] 
As Specific activity [GBq/mg] 
BBB Blood-brain barrier 
CA Carbonic Anhydrase  
CA XII Carbonic Anhydrase 12 
CT Computed Tomography 
EOB End of beam 
EOP End of preparation 
Fab Fragment antigen binding 
GMP Good Manufacturing Practice 
PET Positron Emission Tomography 
phe Extracellular pH 
phi Intracellular pH 
p.i. Post injection  
RIT Radioimmunotherapy 
ROI Region of interest 
RT Room temperature 
SPECT Single Photon Emission Computed Tomography 
Tu/Cl Tumor-to-contralateral 
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2 Introduction 
With an increasing mortality rate from 7.8 Mio deaths in 2008 up to 8.2 Mio deaths in 2012, can-
cer is still one of the leading causes of death worldwide [1, 2]. In order to improve survival rates 
of cancer patients, early detection and effective therapies are mandatory. Nuclear medicine uses 
radiation emitted from incorporated radioactively labelled biomolecules to localize and treat tu-
mor cells in the living organism. Each radionuclide used for radiolabelling shows its individual 
decay characteristics, which makes it suitable for different applications. Positron Emission To-
mography (PET), for instance, utilizes the 511 keV annihilation photons resulting from the inter-
action of positrons emitted by the nuclide and electrons in the surrounding tissue. Consequently, 
a PET - suitable nuclide is characterized by β+ decay [3]. Single Photon Emission Computed 
Tomography (SPECT) on the other hand detects low energy gamma rays from relaxation pro-
cesses of an excited nuclear state [3]. Both imaging techniques, PET and SPECT, are often 
used in combination with an X-ray Computed Tomography (CT) scan to combine metabolic and 
morphologic information with the aim to improve the diagnostic localization of the radiation 
source in the body. Radionuclides with short-ranged radiation from α - or β- - decay with high 
linear energy transfer are commonly used for internal radiation treatment for therapeutic purpos-
es [4, 5]. 
 
For each application, therapy or diagnosis, accumulation of the radioactivity in the desired target 
region is achieved by binding the nuclide to an appropriate carrier molecule. The radioactive 
compound distributes in the organism and accumulates at the desired target. One of the most 
prominent examples for metabolism-based tumor uptake is the tracer [18F]fluorodeoxyglucose 
([18F]FDG) [6, 7]. The high energy demand of fast growing tumor cells leads to an increased glu-
cose uptake. Since FDG is taken up and phosphorylated in the same manners as glucose, glu-
cose metabolism can be quantified by FDG-PET. A more specific tumor uptake can be achieved 
when the radiomolecule binds to the cells using biochemical reactions between the carrier mole-
cule and cell structures [3]. Using a receptor exclusively expressed on the target tissue in com-
bination with a carrier molecule which binds specifically to this target optimizes image quality or 
therapeutic output, while sparing healthy tissue from unnecessary radiation.  
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Such a target is the enzyme carbonic anhydrase (CA XII). It is overexpressed on several tumor 
tissues, for instance breast carcinoma [8-10], astrocytomas [11], gliomas [12-14], renal carcino-
ma [15-17] and ovarian tumors [18]. CA XII is located on the membrane and has a major influ-
ence on the pH stabilization of the cell. The enzyme catalyzes the hydration of CO2 to HCO3-, 
which is a buffer in the cytosol. In general, tumor tissue is known for its acidic extracellular pH 
(pHe) (< 6.9) in comparison to its slightly alkaline intracellular pH (pHi) (> 7.0) [19-22]. A change 
in pHi would significantly affect cell proliferation and cell function. It might even cause apoptosis 
[23-27]. Hence, stabilization of the optimal pH range is essential for the cell, which is why CA XII 
is overexpressed on many tumors. 
 
The fast growth of tumors often leads to a chaotic vascular distribution and insufficient vessel 
function, resulting in a lack of oxygen supply to the cells [21, 28-30]. Additionally, tumors cover 
their large energy demand with a high respiration rate [20, 21, 25]. As a result of these effects 
the tumor cells become hypoxic [21, 28]. Therefore, tumor cells use extensively anaerobic gly-
colysis to ensure their energy supply. In comparison to healthy cells, they produce a much high-
er amount of acidic metabolic products in the cytosol which would result in an acidic pHi [21, 31-
34], since only CO2, but not H+ can easily cross the membrane [21, 35-37].  
 
A cell can rely on several pH regulating mechanisms to extrude protons from the cytosol. An 
active H+ transport is achieved by Na+/H+ exchangers [21, 32, 38-41], proton channels [42] or V-
type ATPase H+ ion pumps [32, 43, 44]. An indirect co-transport of protons is attained by mono-
carboxylate transporters [32, 38, 45]. Additionally, protons can be buffered by intracellular avail-
able HCO3- ions, resulting in CO2 which is able to leave the cell [21, 31]. To enable this buffering 
reaction, bicarbonate ions have to be available in the cytosol. Transporter systems such as Cl- - 
HCO3- exchanger [46] or Na+ - HCO3- transporter proteins [21] transfer the ions into the cell by 
diffusion. For these mechanisms, bicarbonate has to be extracellularly available. This is 
achieved by tumor-associated transmembrane carbonic anhydrases (CA) [38, 47-49]. Figure 2-1 
shows a schematic illustration of a tumor cell in context with these ph regulating processes.  
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Figure 2-1: Schematic drawing of the pH regulation in a tumor cell. Next to extruding H+ with exchange or 
transport mechanisms, bicarbonate is used as a buffer system. The escaped CO2 is extracellularly con-
verted into bicarbonate by carbonic anhydrases and transported back into the cell. 
 
Membrane-tethered CAs with an extracellularly located active site such as CA IX and CA XII 
have been reported to be of significant importance for tumor cells since they use the escaped 
CO2 to provide bicarbonates for transportation back into the cell [21, 31, 50, 51]. CAs are a fami-
ly of zinc metalloenzymes known to catalyze the hydration of carbon dioxide and water to bicar-
bonate and proton (CO2 + H2O →	H+ + HCO3-) [13, 14, 47, 48, 50, 52, 53], as presented in Figure 
2-2. 
 
 
Figure 2-2: Reaction mechanism of the formation of bicarbonate catalyzed by carbonic anhydrases. 
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The reaction is initiated by trapping a water molecule on the zinc ion at the active site, followed 
by the formation of a hydroxide ion [51, 52]. Carbon dioxide is attacked by the nucleophilic hy-
droxide ion and the resulting bicarbonate ion is replaced from the Zn2+ with water, which regen-
erates the initial hydroxide ion and provides the bicarbonate as a buffer to stabilize the cell´s pH 
milieu [51, 52].  
 
The expression of CAs IX and XII has been confirmed on a variety of tumor tissues [50, 54] and 
is even enhanced under hypoxic conditions [10, 12, 22, 49, 50]. As a target in clinical applica-
tions, CA IX has already been intensively investigated [13, 36, 38, 50]. Targeting CA XII might 
equally be interesting since it is expressed on different malignant cells such as breast carcinoma 
[8-10], astrocytomas [11], gliomas [12-14], renal carcinoma [15-17] and ovarian tumors [18]. To 
deliver a radionuclide for diagnostic or therapeutic purposes to CA XII expressing tumor cells, a 
suitable carrier molecule is needed. The tracer should accumulate homogeneously at the tumor 
and not on healthy tissue with - especially for therapy - a long retention time on the target [55].  
 
Radiolabelled biomolecules, such as antibodies, have already been investigated to be promising 
agents for therapeutic and diagnostic approaches in nuclear medicine [56-62]. Antibodies are 
characterized by a molecular mass of approx. 150 kDA and consist of two heavy and two light 
chains (see Figure 2-3). The light and the heavy chains together are forming the antigen binding 
site at the N-terminated area of the antibody.  
 
Figure 2-3: Schematic illustration of an antibody structure containing the N-terminated binding sites on 
the Fab-domains, the C-terminated Fc-domain and the allocation in heavy and light chains.  
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Since a Fab (fragment antigen binding) with approx. 55 kDa consists of one of the two binding 
sites of an antibody, identical target specificity to the full-length antibody can be expected. Nev-
ertheless, the size difference between these two molecules has significant impact on the phar-
macokinetics. In vivo distribution and digestion of antibodies is known to be slow, which result in 
prolonged availability in the blood [63-65]. As a result, the antibody is available for a continued 
distribution in both, target and non-target tissue. In case of radiolabelled antibodies, this may 
entail unintended exposure of healthy tissue and an impaired contrast in nuclear images [55, 
66]. Due to their high molecular weight, full-length antibodies have worse diffusion properties 
than Fab fragments so an inhomogeneous distribution in solid tumors due to a limited vascular 
permeability has been reported [66]. Fab fragments accumulate faster in the tumor and are 
cleared rapidly from the blood through the kidney. This leads to lower tumor uptakes in compari-
son to antibodies [55, 62, 67]. Due to this shortened availability in the blood, radiolabelled Fab 
fragments allow high resolution nuclear imaging since the tumor to background signal is im-
proved in comparison to antibody applications [55, 68]. Fab fragments have just 1/3 of the anti-
body´s molecular weight, resulting in an improved diffusion ability [69, 70]. This contributes to an 
enhanced clearance of normal tissue, better uptake homogeneity in tumors and improved target-
ing of disseminated metastases [62, 66, 67].   
 
In this study, the Fab fragment of the 6A10 antibody was used to target CA XII expressing tumor 
cells. The 6A10 antibody has been shown to be a promising agent for this purpose [13, 14]. Be-
sides its highly specific in vitro CA XII binding capacity this antibody inhibits the catalytic function 
of the target enzyme, which results in antitumor activity both in vivo and in vitro [13, 14]. Further 
modification and radiolabelling of the 6A10 Fab in connection with the confirmation of its pre-
served biological function, as well as in vivo and in vitro experiments are presented in this study.  
 
The first part of this study focused on investigating the possible therapeutic application of radio-
labelled 6A10 Fab against gliomas, which are known to overexpress CA XII in comparison to 
healthy brain tissue [12-14]. Gliomas are the most common brain tumors in adults accompanied 
with poor prognosis for patients [71, 72]. Standard treatment includes maximum surgery of the 
tumor and all visible affected tissue, but due to the gliomas highly infiltrative growth behavior full 
resection of all disseminated tumor cells is nearly impossible [73]. Also, standard radiation and 
chemotherapy cannot prevent long-term recurrences [74]. Local intracavitary radioimmunothera-
py (RIT) offers an alternative therapeutic approach, where a radiolabelled conjugate is locally 
applied into the resection cavity, from where it diffuses into the surrounding brain tissue and tar-
gets disseminated glioma cells through direct irradiation [59, 74, 75]. A fast distribution in the 
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brain tissue in combination with a highly specific binding to malignant cells is mandatory for a 
successful therapy. Previous studies investigated the diffusion properties of anti-tenascin full-
length antibodies against their Fab fragments in rat brains and confirmed the superior diffusion 
velocity and distance of the fragments [76]. Using even smaller molecules to further increase the 
diffusion gradient and therefore the diffusion distance [69, 70] is not expected to be of ad-
vantage, since most tumor recurrences occur in a 2 cm margin around to the resection cavity 
[77]. A wider diffusion extent would increase the exposure of healthy tissue, which should be 
avoided. Since an antibody fragment with moderate diffusion properties shows the most promis-
ing characteristics for RIT purposes, this study investigates the possibility to use the 6A10 Fab 
for RIT applications against glioblastomas. 
 
To generate a significant therapy effect on the spread tumor cells and simultaneously spare as 
much healthy tissue as possible, the 6A10 Fab has to be radiolabelled with a suitable radionu-
clide. Nuclides like iodine-131 and yttrium-90 have previously been used for RIT studies [74, 78, 
79]. Yttrium-90 is not considered in this study, since it has a soft tissue range of 11 mm [80], 
which is too large to precisely irradiate small targets in otherwise healthy tissue. Iodine-131 and 
lutetium-177 on the other hand offer similar soft tissue ranges (approx. 2 mm), half-lifes (8 days 
and 6.7 days, respectively) and beta decay characteristics [80]. In addition to the emission of 
therapy-relevant particles, it is clinically advantageous to use a nuclide with photon emission for 
imaging. However, lutetium-177 is used in this study since it offers, due to its 208 keV gamma 
energy, a better SPECT imaging quality than iodine-131. This improved imaging data can be 
used for individual patient dose calculations in future therapy trials. Lutetium-177 is furthermore 
available in high radiopharmaceutical quality, in accordance to the Good Manufacturing Practice 
(GMP) guidelines, which is essential for the clinical application of the produced radioconjugate. 
 
A first evaluation of the 177Lu-labelled 6A10 Fab with regard to a potential application for RIT was 
performed in this study. These characterization experiments included in vitro stability studies in 
labelling buffer, cerebrospinal fluid and plasma, in vitro blocking studies on tumor slices, autora-
diography and HE-staining of tumor slices, biodistribution studies and proof-of-principle planar 
imaging and SPECT/CT experiments on mice bearing a glioma tumor xenograft.  
 
Besides gliomas, CA XII expression has been reported on different tumors cells such as breast, 
ovarian or lung cancer. Extending the range of application of the 6A10 Fab beyond the local gli-
oblastoma therapy might therefore be a promising development in anti-cancer research. By us-
ing a suitable β+ emitting nuclide for radiolabelling, this Fab fragment could be used for PET-
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based diagnostics of CA XII expressing tumors. Since this includes a systemic administration of 
the compound, the used radionuclide should have appropriate characteristics in correlation with 
the Fab´s pharmacokinetic and metabolic profile. Full-length antibodies have previously been 
radiolabelled with nuclides such as zirconium-89  (T1/2 = 3.27) [81, 82] or iodine-124 (T1/2 = 4.18) 
[82], which enable PET-imaging of even very slow biological distribution processes due to their 
long half-lifes. To track the fate of a Fab fragment in vivo, which has a faster pharmacokinetic 
profile in comparison to antibodies, a radionuclide with a more suitable, intermediate half-life 
such as copper-64 (T1/2 = 12.7 h) is promising. Copper-64 is superior to zirconium-89 and iodine-
124, since its decay scheme has an additional β- component (probability 39.0 (3)%) [83-85]. This 
may even enable therapeutic applications [86-88]. Labelling of biological carrier molecules such 
as antibodies and their fragments with copper-64 is commonly achieved by using chelators, such 
as Diamsar, NOTA, NODA-GA, PCTA and their derivatives [89, 90]. Several promising studies 
of chelator-conjugated, 64Cu-radiolablled antibodies and their fragments have recently been pub-
lished against pancreatic cancer [91], malignant lymphoma [92], breast cancer [93-95], ovarian 
cancer [94], head and neck cancers [96] and CA IX expressing malignant tissue [97]. Other 
types of molecules, such as RGD-peptides or RGD2-BBN heterotrimers have also been radio-
labelled with copper-64 via chelators and investigated for PET-imaging of gliomas and prostate 
cancer, respectively [98, 99]. Due to this well-established coordination chemistry, radiolabelling 
of the 6A10 Fab with copper-64 is feasible and very promising for further investigations. 
 
The production of copper-64 according to the 64Ni(p,n)64Cu reaction in a biomedical cyclotron 
has already been established by several groups [100-105]. However, all production related steps 
including electrochemical deposition of the nickel-64 solid target, irradiation, dissolution and puri-
fication of the irradiated target, and final preparation of the copper-64 for labelling purposes were 
performed using individual methods and mostly custom-made, semi-automated setups. An au-
tomated commercially available setup for this purpose (the so-called “Alceo” modules), is pro-
vided by Comecer S.p.A. (Castel Bolognese, Italy). In this study, the production of copper-64 
using the first generation Alceo modules was evaluated and established. The amount of co-
produced radionuclides, the radiochemical purity and identity after separation, as well as the 
non-radioactive metal impurities and the molar activity were determined to characterize the 
product with regard to further radiolabelling applications. Finally, the 6A10 Fab was radiolabelled 
with copper-64 for the first time. The conjugate was systemically injected into mice bearing a CA 
XII-expressing tumor xenograft and proof-of-principle PET-imaging experiments were performed.  
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3 Studies 
177Lu-labelled 6A10 Fab for therapeutic RIT applications 
The 6A10 Fab fragment was firstly radiolabelled and evaluated for the use as a therapeutic 
agent against glioma recurrences in this study. The Fab was conjugated with the chelator p-
SCN-Bn-CHX-A´´-DTPA at alkaline pH. This induces the formation of a thiourea bond between 
the chelators´ isothiocyanate residue and the amino groups of lysines, located in the amino acid 
sequence of the 6A10 Fab. Using nap-5 columns, unbound chelator was removed and the 
amount of bound chelator per molecule Fab was determined to be 1:0.96 via Maldi-TOF analy-
sis. A concentration calculation of the conjugation product was performed based on photometric 
absorption. The lutetium-177 was complexed to the chelator in a slightly acidic sodium acetate 
buffer, yielding a specific activity (AS) of up to 1.5 GBq/mg with radiochemical purities >96%. 
Figure 3-1 shows the structural drawing of the final radioimmunoconjugate.  
 
Figure 3-1: Structural drawing of the [177Lu]LuDTPA-Fab. 
 
The absence of any free lutetium-177 or [177Lu]LuDTPA was confirmed using radio-TLC tech-
niques. Flow cytometry investigations with the conjugated and radiolabelled Fab on CA XII ex-
pressing cell lines were performed, which verified the sustained biological function of the Fab in 
vitro. The immunoconjugate was incubated in cerebrospinal fluid (37 °C), plasma (37 °C), and 
labelling buffer (RT) over 96 h, which resulted in a remaining radiochemical purity of 86%, 90% 
and 90%, respectively. Autoradiographic and microscopic examinations of glioma tumor slices 
revealed that areas with high activity accumulation also have a high cell density and vice versa. 
Furthermore, an in vitro blocking experiment on tumor slices resulted in a 50% reduced uptake 
after blocking the CA XII with native 6A10 antibody.  
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A suitable animal model would require tumor inoculation and resection followed by chemo- and 
radiotherapy and finally local application of the Fab. Since such a model is currently not availa-
ble, a xenograft animal model was used in this study to determine the in vivo behavior of the 
conjugate. SCID-mice with glioma xenografts on the right flank were used for biodistribution 
studies. The mice were systemically injected with 4.3 ± 0.4 MBq of the 177Lu-labelled conjugate 
and sacrificed after different time points (1 h, 3 h, 6 h, 24 h, 48 h). The relevant tissue was col-
lected, the distribution of the radioactive compound was determined via gamma counter meas-
urement, decay corrected to the time of sacrifice, and expressed as percentage injected dose 
per gram (%ID/g). After 3 h, the tumor retained a maximum of activity with 3.1 ± 0.9%ID/g, suc-
cessively decreasing to 1.8 ± 0.5%ID/g after 48 h. Compared with other studies investigating 
radiolabelled Fab fragments, such as Mendler et al. 2015 [68, 106], this means a moderate up-
take. High kidney retention was observed over all time points, with 55.6 ± 13.0%ID/g even after 
48 h, which may be critical for therapeutic applications. Nevertheless, the aim of this study was a 
local RIT application, so the compound would not leave the brain in the first place, assuming on 
an intact blood-brain barrier (BBB) after tumor resection. According to the biodistribution results, 
the brain does not accumulate activity which is an indicator for the inability of the Fab to cross 
the BBB. 
Finally, first planar imaging experiments on a clinical T2 Siemens Symbia were performed 4 h 
p.i. on tumor bearing mice (n = 5), after the injection of 16.6 ± 2.1 MBq, resulting in a good visu-
alization of the tumor. The tumor-to-contralateral ratio (Tu/Cl) determined by region of interest 
(ROI) analysis was approx. 2/3 smaller than the one determined by biodistribution, which is 
mainly a consequence of using a human scanner with a limited spatial resolution for small-
animal imaging.  
As a consequence, the 177Lu-labelled 6A10 Fab was found to be a promising compound for fur-
ther investigations with regard to RIT application. Detailed descriptions of all relevant material, 
methods and corresponding results in conjunction with a detailed discussion is provided in 
Fiedler et al. 2018 [107]. 
 
A successful RIT approach against gliomas can only be guaranteed by using an optimized 
amount of radioactivity applied in the resection cavity. SPECT/CT imaging is a valuable tool to 
generate the data necessary for those dose calculations. Thus, for one animal (5 h p.i.) an addi-
tional 60-minute SPECT/CT on a dual-headed T2 Siemens Symbia was acquired directly after 
the first planar scintigraphy. The SPECT data acquisition was based on a 180°-rotation of both 
detectors in 60 projections, a detector radius of 10 cm and a measurement time of 60 s per view. 
Projections were measured in 256 x 256 pixels with zoom 2 (isotropic voxels of 1.2 mm). The 
  Studies 
  13 
SPECT image was reconstructed using CT-based attenuation correction, triple-energy-window 
scatter correction (lower peak: 170 keV ± 20%, upper peak 240 ± 20% keV ± 15%) and com-
pensation for geometrical detector response as described in Delker et al. [108]. Figure 3-2 
shows the coronal and transversal SPECT/CT image slice of this mouse. In analogy to the pla-
nar scintigraphy and biodistribution experiments, kidneys and bladder were strongly visible. ROI 
analysis revealed a tumor-to-contralateral ratio of 2.4. This value differs from the corresponding 
mean ratio of 3.3 ± 0.3 generated from planar scintigraphy, since SPECT/CT values are correct-
ed for attenuation and scattering effects and the exclusion of signal superposition is possible. 
 
Figure 3-2: Coronal (A) and transversal (B) SPECT/CT image of a mouse 5 h after the injection of 16.1 
MBq 177Lu-6A10 Fab. The tumor on the right shoulder is indicated by white arrows. 
 
64Cu-labelled 6A10 Fab for diagnostic PET applications 
Copper-64 is considered as a suitable nuclide to label the 6A10 Fab for the possible use as a 
diagnostic agent in PET studies. The cyclotron-based production of this radiometal using the 
automated Alceo setup was evaluated in this study in order to establish a routine production of 
copper-64 suitable for radiolabelling.  
The Alceo setup consists of three modules to cover all necessary steps of the copper-64 produc-
tion: the “EDS”, where the electrochemical nickel-64 deposition on the so-called “shuttle” and the 
dissolution of the irradiated nickel-64 target takes place, the “PTS” which is responsible for target 
positioning and cooling during the irradiation and the “PRF” for separation of the irradiated prod-
uct from possible co-products and target material. The Alceo modules use a dynamic electro-
chemical deposition method, in which the nickel-64 solution is pumped through the electrochem-
ical cell at a constant flow between 1.2 – 1.4 ml/min. Up to 85 mg nickel-64 were deposited in 
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20-24 h at 2.6 V and a varying current. The shuttle equipped with the nickel deposit was auto-
matically sent through tubes to the PETtrace 800 series cyclotron for irradiation. The beam posi-
tion was successfully confirmed to be in the beamline by performing a paper burn test. Beam 
parameters between 11 – 14.5 MeV, up to 5 h irradiation duration and up to 30 µA were tested 
in this study. High irradiation currents and long durations with a 14.5 MeV proton beam have so 
far resulted in yields greater than 5 GBq copper-64 at the end of beam (EOB). Irradiation by-
products were separated from the copper-64 fraction and quantified using gamma spectroscopy. 
The purified copper-64, available in 9 ml hydrochloric acid (HCl), was evaporated to dryness and 
re-dissolved in 400 µl 0.1 M HCl in order to set appropriate conditions for further radiolabeling 
experiments. Gamma spectroscopy analysis and half-life determination confirmed the nuclide 
identity of copper-64 and its purity (>99%). The molar activity (Am) was calculated using a TETA 
titration method introduced by McCarthy et al. 1997 [100] and decayed samples of the product 
were analyzed via ICP-OES. The amount of metal impurities was used to evaluate the module 
cleaning method and a correlation with the measured molar activity was made. Improving the 
cleaning procedure has led to an AM of up to 133 GBq/µmol. The insufficient reproducibility dur-
ing target preparation was discovered to be one of the most limiting factors when using the 
Alceo modules for the automated production of copper-64. Nevertheless, it was possible to pro-
vide copper-64 in good yields, high purity and moderate molar activity for medical purposes.  
Finally, the 6A10 Fab fragment was conjugated with p-NCS-Bn-NODA-GA, radiolabelled with the 
produced copper-64 (see Figure 3-3) with an AS of 208.6 ± 49.7 MBq/mg and a radiolabelling 
purity of higher than 93%. A first PET image was generated on a tumor xenograft mouse model. 
A full description of the performed experiments concerning the copper-64 production, characteri-
zation, radiolabelling and final PET application with the 6A10 Fab, including all relevant material, 
is provided in Fiedler et al. 2018 [109]. 
 
 
Figure 3-3: Structural drawing of the [64Cu]CuNODA-GA-Fab. 
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PET imaging and biodistribution of four tumor bearing mice (M1, M2, M4 and M5), injected with 
the 64Cu-labelled 6A10 Fab, were performed. Data gained from the biodistribution experiments 
with 64Cu-6A10 Fab were subsequently compared to the data previously obtained from biodistri-
bution with the 177Lu-6A10 Fab. 
Tumors were subcutaneously inoculated with 5x106 U87 cells into the right shoulder of female 
SCID-mice (6 - 8 weeks, 20 - 25 g). A growth time of 12 days resulted in tumor sizes of 140 ± 
89 mm3. The mice were intravenously injected with 13.1 ± 2.4 MBq of the 64Cu-labelled 6A10 
Fab (approx. 250 µl). M1 and M2 were scanned 4 h p.i. (see Figure 3-4) and M3 and M4 23 h 
p.i. (see Figure 3-5) for 1 h on an Inveon P120 µPET device under constant anaesthesia. The 
images were analyzed with the Inveon Research Workplace software and tumor-to-contralateral 
ratios were determined by ROI analysis, using a tumor ROI based on 40% threshold. Immediate-
ly after the scans the mice were sacrificed, all relevant tissue was harvested, collected, weighed 
and measured by gamma counter. These data were decay corrected to the time of biodistribu-
tion (5 h p.i. for M1 and M2; 24 h p.i. for M4 and M5) and expressed as %ID/g (see Table 3-1). 
This table additionally includes the comparison between the 64Cu- and the 177Lu-generated bio-
distribution data at similar time points (64Cu-compound 5 h p.i. with the 177Lu-compound 6 h p.i., 
and the results of both studies 24 h p.i.).  
 
Both, biodistribution and imaging data showed good tumor uptake and high accumulations in 
organs such as kidney, liver, bladder, spleen and the intestines. Especially in comparison to the 
values obtained from the 177Lu-labelled compound it is notable, that the tumor as well as every 
other harvested tissue shows higher amounts of the 64Cu-labelled compound. Next to the biodis-
tribution data listed in Table 3-1, a graphical comparison of the results gained 5 h, 6 h and 24 h 
p.i. is shown in Figure 3-6 and Figure 3-7, respectively. 
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Figure 3-4: PET images of M1 and M2 4 h after the injection of 14.7 MBq and 13.9 MBq of the 64Cu-6A10 
Fab, respectively. Tumors on the right shoulder are indicated with white arrows. 
 
 
Figure 3-5: PET images of M4 and M5 23 h after the injection of 9.6 MBq and 14.2 MBq of the 64Cu-6A10 
Fab, respectively. Tumors on the right shoulder are indicated with white arrows. 
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Table 3-1: Comparison of the biodistribution results (in %ID/g) gained using n = 2 and n = 4 mice injected 
with 64Cu- and 177Lu-labelled 6A10 Fab, respectively. 
 
64Cu-Fab  
(5 h p.i.) 
177Lu-Fab  
(6 h p.i.) [107] 
64Cu-Fab  
(24 h p.i.) 
177Lu-Fab  
(24 h p.i.) [107] 
Blood 1.9 ± 0.2 1.2 ± 0.3 0.9 ± 0.1 0.2 ± 0.1 
Heart 1.7 ± 0.2 0.9 ± 0.2 1.4 ± 0.2 0.6 ± 0.2 
Lung 3.3 ± 0.2 1.5 ± 0.7 3.9 ± 1.0 0.5 ± 0.3 
Liver 13.5 ± 1.6 5.4 ± 0.7 8.2 ± 1.3 2.6 ± 1.0 
Spleen 6.0 ± 0.7 1.8 ± 0.7 4.2 ± 0.9 2.1 ± 1.1 
Stomach 2.5 ± 0.4 0.6 ± 0.1 1.9 ± 0.2 0.5 ± 0.1 
Small int. 3.3 ± 0.4 0.6 ± 0.1 2.5 ± 0.3 0.4 ± 0.1 
Large int. 4.4 ± 0.4 1.5 ± 0.4 3.3 ± 0.5 0.7 ± 0.2 
Kidney 84.2 ± 19.7 83.5 ± 18.5 21.4 ± 4.9 93.1 ± 5.0 
Brain 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 
Muscle 0.5 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 0.3 ± 0.1 
Tumor 6.9 ± 1.6 3.0 ± 0.8 5.7 ± 2.0 2.5 ± 0.6 
Thyroid 1.3 ± 0.4 0.4 ± 0.1 1.0 ± 0.2 0.4 ± 0.3 
 
Figure 3-6: Biodistribution results 6 h and 5 h after injecting tumor xenograft bearing mice with 4.3 ± 
0.4 MBq 177Lu-6A10 Fab (n = 4) [107] and 13.1 ± 2.4 MBq 64Cu-6A10 Fab (n = 2). 
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Figure 3-7: Biodistribution results 24 h after injecting tumor xenograft bearing mice with 4.3 ± 0.4 MBq 
177Lu-6A10 Fab (n = 4) [107] and 13.1 ± 2.4 MBq 64Cu-6A10 Fab (n = 2). 
Molecules with the size of a Fab undergo mainly renal metabolic processes. As a result, an ac-
tivity of approx. 84%ID/g was found in the kidney 5 and 6 h p.i. in both studies. 24 h p.i. the 64Cu-
compound shows a more rapid clearance (20%ID/g) in comparison to the 177Lu-compound (over 
90%ID/g). Protein-chelate-metal-conjugates are metabolized in the kidney´s lysosomes. Lyso-
somes catabolize these complexes into metal-chelate fragments, which cannot cross the cell 
membrane easily and therefore show a long retention in the kidney [110, 111]. The first results of 
this study indicate, that the [64Cu]CuNODA-GA complex may overcome the lysosomes mem-
brane much faster than the [177Lu]LuDTPA complex. The liver accumulated approx. 3 times more 
of the 64Cu-compound than the 177Lu-compound with a slow reduction from 13.5 ± 1.6 to 8.2 ± 
1.3 %ID/g after 24 h, similar to the spleen which shows three times more activity 5 h p.i. and two 
times more activity after 24 h. The blood and other tissues also retained increased amounts of 
activity of the 64Cu-labelled in comparison to the 177Lu-labelled compound. Most importantly, the 
tumor uptake was improved using the 64Cu-Fab, with 6.9 ± 1.6 %ID/g and 5.7 ± 2.0 %ID/g at 5 h 
and 24 h p.i., respectively, which was twice as high compared to the 177Lu-Fab uptake with 3.0 ± 
0.8 ID/g and 2.5 ± 0.6 %ID/g. Conjugation and radiolabelling of a molecule with different chelat-
ing agents and radionuclides are known to alter the pharmacokinetics of the compound signifi-
cantly. This effect may also be visible in this study, as NODA-GA conjugation and 64Cu-labelling 
seems to result in enhanced diffusion properties and improved vascular permeability of the 6A10 
Fab, evidenced by a more persisting activity retention of the 64Cu-compound in all tissues com-
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pared to the 177Lu-compound 24 h p.i.. In vivo stability data for the compound is not yet available, 
therefore radiometal loss from the conjugate, for example through trans-chelating processes, 
cannot be excluded. Several proteins are known to bind copper in the human body and might 
therefore have a major influence on the activity distribution observed in this study. Superoxide 
dismutase for instance, which is strongly present in liver, kidney, adrenal and red blood cells, 
binds copper and leads to an enhanced retention of the metal in the corresponding tissue [112-
114] in case of copper-64. The measured activity in the liver might also be caused by Cerulo-
plasmin, a copper-storage protein synthesized in the liver, which is able to bind up to 6 atoms of 
the metal in its structure [112, 113].  
 
A comparison of all measured tumor-to-contralateral ratios calculated from biodistribution and 
PET data, the amount of injected activity and the individual tumor volumes in mm3 are provided 
in Table 3-2. The table also revealed that tumor-to-contralateral ratios from biodistribution and 
PET differ slightly. Limitations of the PET resolution might lead to too small activity quantifica-
tions in the tumor with the result of decreased tumor-to-contralateral ratios. Especially small 
structures with little activity uptake are affected by those limitations, best visible at M4 with the 
smallest tumor and the lowest injected activity.  
Table 3-2: Tumor volume, applied activity and the correlating Tu/Cl values generated from biodistribution 
and PET data of each mouse investigated with the 64Cu-compound. 
Mouse Tumor vol-ume [mm3] 
Inj. Activity 
[MBq] Tu/Cl – Biodis. Tu/Cl - PET 
M1  240 14.7 15.2 (5 h p.i.) 12.0 (4 h p.i.) 
M2  190 13.9 12.6 (5 h p.i.) 11.5 (4 h p.i.) 
M4 60 9.6 14.6 (24 h p.i.) 9.9 (23 h p.i.) 
M5 70 14.2 17.8 (24 h p.i.) 16.6 (23 h p.i.) 
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4 Conclusion and Outlook 
In this study, the CA XII targeting 6A10 Fab, radiolabelled with lutetium-177 or copper-64, was 
studied as a potential new therapeutic and diagnostic anti-cancer agent in medical applications.  
 
177Lu-labelled 6A10 Fab for therapeutic RIT applications 
To produce a compound for local intracavitary RIT against the recurrences of resected gliomas, 
the 6A10 Fab was conjugated with DTPA and radiolabelled with lutetium-177 for the first time. A 
comprehensive in vitro and in vivo characterization confirmed the conjugate to be suitable for 
this application.  
In this study, a tumor-xenograft model was used to investigate the compound´s pharmacokinet-
ics although this model does not entirely reflect the clinical situation. But an animal model for 
investigating a therapeutic approach similar to the final application would require an inoculated 
tumor to be removed, followed by radio- and chemotherapy. The local application of the drug 
has to occur after a sufficient recovery time to guarantee an intact BBB. However, such a com-
plex animal model is not available so far. 
The approach of local intracavitary RIT using radiolabelled antibodies, such as 131I-antitenascin, 
has already been established in several clinical studies, resulting in an improved survival time of 
patients suffering from gliomas [74, 78]. Since this work demonstrated the highly promising 
characteristics of the 177Lu-labelled 6A10 Fab for RIT purposes, a clinical trial is currently in 
preparation to treat glioma patients with the compound. The high radiopharmaceutical quality of 
the compound for first in-human applications will be ensured by the establishment of a GMP 
compliant production. 
To spare sensitive organs from unintended exposure during therapy, any activity leakage 
through the BBB has to be reduced or even avoided. Biodistribution studies on mice showed no 
brain accumulation after a systemic application, which might indicate the compounds incapability 
to cross the BBB. In order to further guarantee the brain´s integrity a so-called leakage test is 
part of pre-therapeutic examinations of RIT patients [74].  
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Production of the PET nuclide copper-64 
In order to use the 6A10 Fab fragment for PET applications, a fully automated production of 
copper-64 utilizing the Alceo modules was successfully established and resulted in copper-64 
with good radiolabelling quality, high radioactive yields and excellent radiochemical purity. Fur-
ther improvement of the process reproducibility may be achieved by setup changes, such as 
line-shortening, or by using a system based on disposable kits. Such a system would also re-
duce non-radioactive metallic impurities, thus increasing the molar activity of the produced cop-
per-64. 
 
64Cu-labelled 6A10 Fab for diagnostic PET applications 
The 6A10 Fab was conjugated with NODA-GA and successfully radiolabelled with the produced 
copper-64, resulting in a compound well suitable for the proof-of-principle PET imaging experi-
ments performed in this work. Biodistribution results further revealed a good tumor uptake, even 
superior to the tumor uptake previously determined with the 177Lu-compound. All tissue samples, 
except kidney, showed a longer retention time for the 64Cu-compound compared to the 177Lu-
compound. This encourages further investigations of the compound for applications in PET di-
agnostics of CA XII expressing diseases, e. g. breast cancer. Such investigations will comprise 
biodistribution and PET imaging experiments at different time points, including in vivo blocking 
strategies to confirm the specific tumor uptake of the conjugate. 
 
 
 
 
The radiolabelled 6A10 Fab investigated in this work showed highly promising characteristics for 
its application in nuclear medicine. Radiolabelled with 177Lu, a phase I clinical trial for the treat-
ment of glioma patients with the 6A10 Fab will be initiated shortly. Furthermore, the implementa-
tion of the above suggested improvements regarding the 64Cu-labelled 6A10 Fab will be an im-
portant step towards its application in clinical PET studies. 
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Introduction: Due to their infiltrative growth behavior, gliomas have, even after surgical resection, a high
recurrence tendency. The approach of intracavitary radioimmunotherapy (RIT) is aimed at inhibiting tumor
re-growth by directly administering drugs into the resection cavity (RC). Direct application of the radioconjugate
into the RC has the advantage of bypassing the blood-brain barrier, which allows the administration of higher
radiation doses than systemic application. Carbonic anhydrase XII (CA XII) is highly expressed on glioma cells
while being absent from normal brain and thus an attractive target molecule for RIT. We evaluated a CA XII-
specific 6A10 Fab (fragment antigen binding) labelled with 177Lu as an agent for RIT.
Methods: 6A10 Fab fragment was modified and radiolabelled with 177Lu and characterized by MALDI-TOF, flow
cytometry and radio-TLC. In vitro stability was determined under physiological conditions. Biodistribution
studies, autoradiography tumor examinations and planar scintigraphy imaging were performed on SCID-mice
bearing human glioma xenografts.
Results: The in vitro CA XII binding capacity of the modified Fab was confirmed. Radiochemical purity was
determined to be N90% after 72 h of incubation under physiological conditions. Autoradiography experiments
proved the specific binding of the Fab to CA XII on tumor cells. Biodistribution studies revealed a tumor uptake
of 3.0%ID/g after 6 h and no detectable brain uptake. The tumor-to-contralateral ratio of 10/1 was confirmed
by quantitative planar scintigraphy.
Conclusion: The radiochemical stability in combinationwith a successful in vivo tumor uptake shows the potential
suitability for future RIT applications with the 6A10 Fab.
© 2018 Elsevier Inc. All rights reserved.
1. Introduction
WHO grade IV Glioblastoma multiforme (GBM) represent the most
aggressive and common subtype of brain tumors [1,2]. Despite
improvements in surgery and radio- and chemotherapy approaches,
the clinical prognosis for GBM patients is still desperate [3,4]. Due to
their invasive growth, GBM cannot be resected completely even by
radical surgery. Consequently, almost all GBM patients succumb to
local recurrence close to the resection margin within 1–2 years after
diagnosis [1,2,5–7]. For improved therapy of these infiltrating cells,
intracavitary radioimmunotherapy (RIT) has been suggested as
interesting option in the past [2,8,9]. Radioimmunoconjugates were
directly injected into the resection cavity via an implanted Ommaya-
reservoir and disseminated tumor cells were targeted through diffusion
processes of the compound. Local treatment in the brain also enables
the application of higher doses, in comparison to systemic application,
because sensitive organs such as kidneys and liver are spared. Among
other studies [5,10–12], Reulen et al. [9] recently reported on the
long-term results of fractionated RIT with 131I and 90Y-labelled
monoclonal antibody directed against tenascin C, an extracellular
matrix glycoprotein which is ubiquitously expressed by malignant
glioma cells, but only minimally expressed in normal brain tissue.
They observed an increased median survival time of 25.3 and 77.2
months for GBM patients and patients with anaplastic astrocytoma,
respectively, which was significantly longer than that described for
historic control patients (15 and 36 months, respectively) [13–16],
indicating the high clinical potential of RIT.
Carbonic anhydrase XII (CA XII) is a new, promising target molecule
for RIT of gliomas. CA XII is a membrane-tethered enzyme that is
Nuclear Medicine and Biology 60 (2018) 55–62
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overexpressed by glioma cells while being absent from healthy brain
tissue [17]. To cover their energy demand, aggressively proliferating
tumor cells are characterized by extensive anaerobic glycolysis, which
causes intracellular acidification. Due to its catalytic properties during
the conversion of CO2 and H2O to HCO3− and H+, CA XII is essential for
the pH stabilization and is overexpressed on the glioma cells [17,18],
which makes it a suitable target for glioma therapy. The 6A10 antibody
binds very specifically to CA XII [17,18], and is therefore considered as a
possible tracer for the intracavitary RIT after tumor resection. Better
diffusion properties are expected from the smaller Fab fragment, so
the aim of this study was to evaluate the radiolabelled 6A10 Fab
fragment with regard to a possible future clinical application. The Fab
was therefore modified with p-SCN-CHX-A″-DTPA (in the following
abbreviated as DTPA), radiolabelled with 177Lu and extensively
characterized in vitro and in vivo.
2. Materials and methods
Unless otherwise stated, all analytic grade chemicals and expend-
able items were purchased from Sigma Aldrich (Taufkirchen,
Germany), Merck (Darmstadt, Germany), Carl Roth (Karlsruhe,
Germany) or Eppendorf (Hamburg, Germany).
2.1. Conjugation of DTPA with 6A10 Fab
The 6A10 Fabwas produced in CHO cells, purified on a CaptureSelect
column (Thermo Fisher, Munich, Germany) and delivered in concentra-
tions of up to 5 mg/ml in phosphate buffered saline (PBS). UsingAmicon
Ultra 2 ml ultracentrifugal (10 kDa cutoff) devices, the buffer was
exchanged to 0.1 M phosphate buffer pH 8.5 (Braun, Melsungen,
Germany) with concomitant volume reduction to a concentration up
to 7.2 mg/ml [19]. As alternative procedure, buffer exchange was also
achieved using size exclusion chromatography. Therefore, nap-5 col-
umns (GE-Healthcare, Munich, Germany) were pretreated with 10 ml
of the phosphate buffer, a sample volume b 0.5 ml was applied to the
resin and elutedwith 1 ml buffer. The re-buffered productwas collected
in fractions. The concentration of the processed Fab was determined by
measurement of the photometric absorption at 280 nm(Ultrospec 1100
photometer by Amersham Biosciences now GE Healthcare, Munich,
Germany), Quartz UPRASIL® precision cell by Hellma Analytics
(Mühlheim, Germany), using an unprocessed Fab calibration standard.
A 10-fold molar excess of p-SCN-CHX-A″-DTPA (Macrocyclics, Dallas,
Texas) was added to the Fab and incubated in an Eppendorf
Thermomixer at 37 °C for 1 h. Buffer exchange to 0.01 M sodium acetate
pH 5.3 and removal of unbound DTPA was achieved by ultracentrifuga-
tion or size exclusion chromatography, as previously explained.
Absorption measurement was again used for concentration calculation.
Final product volumes ranged between 500 and 1000 μl. The number of
bound chelator molecules per Fab was analyzed by the Protein Analysis
Unit (Ludwig-Maximilians-University Munich) using MALDI-TOF
analysis.
2.2. 177Lu-labelling with DTPA-6A10 Fab-conjugate
The required amount of Fab-DTPA conjugate (0.1–1 mg)was diluted
with 50–100 μl 0.1 M sodium acetate pH 5.3. 150–1500MBq of [177Lu]
LuCl3 in 0.04 M hydrochloric solution (EndolucinBeta® from ITG,
Garching, Germany) was added to the reaction vessel and incubated
at 37 °C for 1 h. Radio thin layer chromatography (radio-TLC) on ITLC-
SA (Agilent, Waldbronn, Germany) strips with 0.5 M citrate buffer pH
4–5 was performed for quality control purpose. For DC analysis, a
miniGITA (Raytest, Straubenhardt, Germany) and the GINA Star TLC
software was used.
2.3. Flow cytometry
Flow cytometry analysis was performed with a FACSCanto™ Flow
Cytometer (BD Biosciences, Heidelberg, Germany) to determine the
specific binding ability of the conjugated and labelled Fab in comparison
to the unmodified variant on CA XII positive A549 cell line. The cells
were incubated with 6A10 Fab, followed by incubation with a
fluorochrome-coupled secondary antibody. Incubation of the secondary
antibody only, without 6A10, served as control. Furthermore, the CA XII
expression of the cell line used in this study was characterized with
native 6A10 antibody.
2.4. Radiochemical stability
To determine the radiochemical stability of the labelled conjugate, it
was incubated in labelling buffer at room temperature and in a 10-fold
volume excess of human cerebrospinal fluid (CSF) andhumanplasma at
37 °C. CSF and plasmawas extracted from healthy volunteers. At differ-
ent time points (2 h; 4 h; 8 h; 16 h; 24 h; 48 h; 72 h; 96 h) an aliquot of
the conjugate was analyzed with radio-TLC as previously described.
2.5. Cell line
Human glioblastoma cell line U87MGwas received by the American
Type Culture Collection and cultivated in GibcoMEMmedium (Thermo
Fischer Scientific, Munich, Germany), supplemented with 10% Fetal
Bovine Serum and L-Glutamine (both from Biochrom, Berlin,
Germany), and kept under constant conditions of 5% CO2 and 37 °C in
a CB150 incubator (Binder, Tuttlingen, Germany). Cell passages at the
time of tumor inoculation ranged from 12 to 16. As a part of our cell
culture handling routine, all cell lines are regularly checked for
mycoplasma.
2.6. Biodistribution
Female SCID-mice (6–8 weeks, 20–25 g, from Charles River, Sulzbad,
Germany) were subcutaneously injected with 5 × 106 U87MG cells into
the right flank. Tumor sizes of approx. 0.5 cm3 within 2–3 weeks of
tumor growth were aspired. 177Lu-labelled 6A10 Fab was synthesized
as described above and 4.3 ± 0.4 MBq (2.9 ± 0.3 μg Fab) were injected
intravenously into the tail vein. At each time point (1 h; 3 h; 6 h; 24 h;
48 h) 4 mice were sacrificed for biodistribution studies. Blood and
relevant tissue was harvested, collected in tubes, and weighed. The
retained tissue radioactivity was measured by gamma counter (Cobra
Quantum 5003 by Canberra Packard, Schwadorf, Austria), decay
corrected to the time of biodistribution and expressed as percentage
injected dose per gram of tissue (%ID/g).
2.7. Autoradiography and HE-staining
U87MG-xenotransplanted female SCID-mice (n= 6) were injected
with 20.7 ± 1.3 MBq of the labelled conjugate. After 3–50 h tumors
were extracted post mortem, immediately embedded in Tissue-Tek
O.C.T. (Sakura Finetek, Staufen, Germany) and stored at−80 °C. Tumors
were cut into 20 μm slices with a Leica CM1510 S cryostat (Leica
Biosystems, Nussloch, Germany), transferred to microscope slices and
dried. A phosphoric photo screen was exposed overnight to the radiat-
ing tumor slices, and scanned with a Cr 35 Bio scanner (Dürr Medical,
Bietigheim-Bissingen, Germany). Image analysis was performed with
an Aida Image Analyzer v.450. Different intensity areas were compared.
Furthermore, in vitro blocking experiments on tumor slices, har-
vested frommicewhichwere not injectedwith the conjugate, were car-
ried out. The slices were incubated for 1 h with a 100-fold molar excess
of native 6A10 to block CA XII, and afterwards rinsedwith TRIS-HCl. The
dried slices were incubated for 1 hwith 177Lu-labelled 6A10 Fab. Analy-
sis and interpretation of autoradiographs was done as described above.
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Additionally, staining with hematoxylin and eosin (HE-staining)
was performed. The dry slices were rinsed with distilled water, dried,
dyed with hematoxylin and again rinsed with water and a series of
hydrochloric-alcoholic solutions. Subsequent staining with eosin was
followed by rinsing with water, 70%, 96%, 96%, 100%, 100% ethanol and
xylene. The dried slices were covered and microscopically examined
at the Pathology Department of the Ludwig-Maximilians-University
Munich.
2.8. Planar scintigraphy
Mice (n = 5; 6–8 weeks; 20–25 g) were subcutaneously injected
with U87MG cells into the right shoulder to avoid disturbance from kid-
ney and bladder activity in the final image. An average tumor size of 0.5
cm3 was reached after 1.5 weeks of growth time. 16.6 ± 2.1 MBq
radioconjugate was injected via a tail vein catheter. A 60-minute planar
scintigraphyon the isoflurane anesthetized animalswas performed on a
T2 Siemens Symbia for all animals 4 h p.i. using a 20% energy window
around the 177Lu photopeak of 208 keV in combination with a
medium-energy-low-penetration collimator. A 1024 × 1024 imaging
matrix with zoom 2 was chosen. The planar images (pixel size:
0.2997 × 0.2997 mm2) were post-processed via a Gaussian filter with
a FWHM of 3 mm for noise suppression. Afterwards tumor-to-muscle
ratios were evaluated via PMOD (Version 3.609) by drawing circular
ROIs of 2 mm radius at the tumor and at the contralateral thigh muscle.
3. Results
3.1. Conjugation of DTPA with 6A10 Fab
Depending on the chelator quantity, up to 8 centrifugal runs were
necessary to successfully remove unbound DTPA. Unbound DTPA
could also be removed using nap-5 columns. The resulting conjugate
concentration was up to 6mg/ml in 0.01M sodium acetate.
MALDI-TOF analysis revealed a molar ratio of chelator to protein of
1:0.96, with a mass shift from 48,329 kDa to 48,904 kDa, native 6A10
Fab to conjugated Fab respectively.
3.2. 177Lu-labelling of DTPA-6A10 Fab-conjugate
Specific activities of 1.5 GBq/mg Fab, with radiochemical purities
N96% without further purification were achieved. Radio-TLC analysis
of the product revealed the sufficient separation of the radiolabelled
Fab from radiolabelled DTPA and free 177Lu. A representative
chromatogram is plotted in Fig. 1. Free [177Lu]Lu-DTPA or 177Lu was
detectable at Rf-values of 0. 2 ± 0.05 and 1.0 ± 0.1, respectively, while
the Fab remains at the origin.
3.3. Flow cytometry
Flow cytometry confirmed that modification and labelling with
177Lu does not inhibit the characteristic CA XII binding ability of the
6A10 Fab in comparison to its native form. This is shown in part a of
Fig. 2, where conjugated and native Fab-samples are compared using
equivalent serial dilution steps on a CA XII expressing cell line. For
both, similar fluorescent signals were detectable. Part b of Fig. 2 shows
the binding capability of the radiolabelled Fab sample. Using a native
6A10 antibody, the positive CAXII expression of the U87 cells used for
this study was confirmed.
3.4. Radiochemical stability
Data obtained from different production charges were compared
after normalization to 100% radiochemical purity at 0 h and plotted in
Fig. 3. Over a period of 72 h the radiochemical stability of the labelled
conjugate was determined to be N90% in all the tested media. After 96
h, the conjugate maintained a radiochemical purity of 86% in
cerebrospinal fluid and 90% in labelling buffer and plasma.
3.5. Biodistribution
In Table 1 and Fig. 4 the results of the biodistribution study on
U87MG xenotransplanted SCID-mice are summarized. The tumor
showed a quick activity uptake up to 3.1 ± 0.9%ID/g, decreasing to 1.8
± 0.5%ID/g at 48 h. Blood activitywas 6.4 ± 2.2%ID/g after 1 h, followed
by a clearance within the next 24 h. The muscle was characterized by
Fig. 1. Comparison of radio-TLC chromatograms of free 177Lu, 177Lu-labelled DTPA and the final 177Lu-labelled DTPA-6A10 Fab.
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very small uptake, which never exceeded 1%ID/g. High amounts of
activity were detected in the liver and especially in the kidney. Even
after 48 h 3%ID/g retained in the liver. Most activity over all time points
was found in the kidney, which still held an amount of 55.6 ± 13.0%ID/g
after 48 h. The other organs, such as lung, spleen, intestines and stom-
ach are characterized by steady decrease of activity over time. The
brain showed low values below 0.2%ID/g over all time points.
3.6. Autoradiography and HE-staining
Autoradiographic analysis of the tumor slices revealed an inhomoge-
neous activity distribution. Microscopic analysis of HE-stained slices
confirmed furthermore a correlation between cell density and activity
accumulation. Examinations of n = 6 tumors, harvested at different
time points (1 h, 3 h, 5 h, 30 h and 50 h p.i.) confirmed, that areas of
high cell density retain higher activity, and vice versa. A representative
example is given in Fig. 5 on a tumor slice, which is harvested 5 h p.i.
Blocking experiments on tumor slices with 100-fold molar excess of
6A10 antibody (Fig. 6) revealed a 49% decreased uptake of 177Lu-
labelled Fab (n= 8) in comparison to un-blocked slices.
3.7. Planar scintigraphy
Tumors were successfully visualized in the planar scintigraphies at
4 h p.i. (Fig. 7). Besides the tumor on the right shoulder (as indicated
with white arrows), kidneys and bladder were strongly visible. Based
on this preliminary image data, the mean tumor-to-contralateral ratio
(n= 5 mice) was calculated to be 3.3 ± 0.3.
4. Discussion
Improving the overall survival and quality-of-life of glioma patients
by inhibiting tumor recurrence is the aim of intracavitary
radioimmunotherapy. Studies using anti-tenascin C antibody-
conjugates [5,9–12,20] have already indicated the high clinical potential
of RIT in this context. Carbonic anhydrase XII is another attractive target
molecule, because it is not present on healthy brain while being
overexpressed by glioma cells. In order to target CA XII, a specific bind-
ing radioimmunoconjugate is required, which has sufficiently high ra-
diochemical stability. When used for local intracavitary application,
the conjugate should not cross the blood-brain-barrier and is intended
to distribute through diffusion processes into the tissue.
Because the therapeutic effect of intracavitary RIT is based on diffusion
out of the cavity into the adjacent brain, Goetz et al. [21] compared the dif-
fusion properties of full-length anti-tenascin antibodies with those of their
Fab fragments in rat brains. Their study revealed that both, migration ve-
locity and distance were higher for Fabs as compared to whole antibodies.
As the diffusion velocity depends on the molecular size, a variety of
small molecules has been in consideration for RIT, for instance
Fig. 2. Graphic summary of flow cytometry results: a: Evaluation of flow cytometry analysis comparing uncoupled and DTPA-coupled Fab. No significant differences in binding behavior
were observed after conjugating the Fab with DTPA. b: Result of flow cytometry analysis of 177Lu labelled 6A10 Fab (red) in comparison to an isotype control antibody (grey). Successful
binding is indicated by shifts on the x-axis. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. Plots of the radiochemical purities [%] vs incubation time [h] of 177Lu-Fab samples in
labelling buffer, cerebrospinal fluid and plasma (n= 6).
Table 1
Measured biodistribution values in %ID/g in glioma tumor (U87MG) bearing SCID-mice at
1 h, 3 h, 6 h, 24 h and 48 h after the intravenous application of 4.3 ± 0.4 MBq
radioconjugate.
%ID/g
1 h 3 h 6 h 24 h 48 h
Blood 6.4 ± 2.2 2.7 ± 0.3 1.2 ± 0.3 0.2 ± 0.1 0.1 ± 0.01
Heart 1.8 ± 1.1 1.2 ± 0.6 0.9 ± 0.2 0.6 ± 0.2 0.8 ± 0.4
Lung 1.9 ± 1.1 1.7 ± 0.3 1.5 ± 0.7 0.5 ± 0.3 0.3 ± 0.1
Liver 3.5 ± 2.4 5.0 ± 2.9 5.4 ± 0.7 2.6 ± 1.0 3.1 ± 1.1
Spleen 1.7 ± 1.3 2.5 ± 1.2 1.8 ± 0.7 2.1 ± 1.1 1.6 ± 0.7
Stomach 0.9 ± 0.8 0.8 ± 0.3 0.6 ± 0.1 0.5 ± 0.1 0.2 ± 0.1
Small int. 2.6 ± 0.6 1.0 ± 0.2 0.6 ± 0.1 0.4 ± 0.1 0.3 ± 0.1
Large int. 1.7 ± 1.0 2.2 ± 0.6 1.5 ± 0.4 0.7 ± 0.2 0.4 ± 0.1
Kidney 42.9 ± 22.6 84.3 ± 28.1 83.5 ± 18.7 93.1 ± 14.1 55.6 ± 13.0
Brain 0.2 ± 0.1 0.1 ± 0.02 0.1 ± 0.01 0.04 ± 0.01 0.03 ± 0.01
Muscle 0.4 ± 0.1 0.9 ± 1.0 0.3 ± 0.1 0.3 ± 0.1 0.1 ± 0.02
Tumor 2.4 ± 1.0 3.1 ± 0.9 3.0 ± 0.8 2.5 ± 0.6 1.8 ± 0.5
Thyroid 0.6 ± 0.2 0.3 ± 0.5 0.4 ± 0.1 0.4 ± 0.3 0.4 ± 0.3
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pre-targeted 90Y-biotin [22], Peptidic Vector 1,4,7,10-
tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P
[23], 131I-TM-601 [24], 213Bi-DOTA-[Thi8,Met(O2)11]-substance P [25]
etc. Migration of the antibody or other molecules into the surrounding
parenchyma occurs predominantly by diffusion and depends on the
diffusion gradient, the diffusion coefficient and the width and tortuosity
of the extracellular space [21,26,27].
The distance, the molecule travels in the tissue, may be extended by
increasing the diffusion gradient (activity concentration in the resection
cavity), for example by decreasing the molecular size [28,29]. Smaller
molecules, with better diffusion properties and higher diffusion veloci-
ties may spread too far, which results in unintentional high doses on
healthy brain tissue. Very large molecules on the other hand, such as
antibodies (MW approx. 150 kDa) show slower diffusion properties.
In this study, a fab fragment (MW approx. 55 kDa) with a moderate
diffusion and transit time is used, to treat the tumor cells, which have
migrated into the brain tissue adjacent to the resection cavity.
Therefore, the radioactive labelled Fab fragment of the 6A10 antibody
which binds highly specific to human CA XII [17,18] was further
investigated.
Several radionuclides have been considered for radiolabelling the
6A10 Fab. Isotopes such as 131I and 90Ywere already used for RIT studies
[5,9,30]. The 6A10 Fab is intended to bind at the tumor cells infiltrating
the healthy brain tissue, which represent a very small target in compar-
ison to a solid tumor. To spare surrounding tissue, a short range
β-emitting nuclide is favorable. According to the data provided by
NIST (National Institute of Standards and Technology [31]), 90Y and
131I have soft tissue ranges of about 11 mm and 2.2 mm, respectively,
which excludes 90Y for our purpose. 131I and 177Lu have comparable
beta-characteristics, half-lives and soft tissue ranges, but 177Lu offers
with its 208 keV gamma energy a better image quality. Imaging
characteristics of the used radionuclide are mandatory for dose
calculations based on SPECT/CT data, which will be necessary to
calculate the optimal dose for effective tumor treatment. A better
image quality results in more precise dose estimations out of the
imaging data, which is why 177Lu is favorable over 131I in this study.
Furthermore, 177Lu for labelling purposes is easily available in GMP-
quality and offers convenient radiolabelling strategies [19,32–35].
Previous studies with 177Lu-labelled proteins, such as cetuximab
[34,36–39] have already investigated the suitability of p-SCN-CHX-A″-
DTPA for this purpose. It was also reported, that DTPA offers the ability
of high labelling yields at ambient temperature in combination with
suitable in vivo stability.
Modifying the protein with this DTPA derivate and further
radiolabelling with 177Lu was done based on methods reported
previously [19,39]. High radiochemical purities of up to 99% were
Fig. 4. Biodistribution profile in %ID/g at 1 h, 3 h, 6 h, 24 h and 48 h after the intravenous application of 4.3± 0.4 MBq radioconjugate.
Fig. 5. Autoradiography image of a U87MG tumor slice, harvested from a tumor bearing
SCID-mouse 5 h p.i. The typical inhomogeneous activity distribution is analyzed by
microscopic examinations after HE-staining. One low (a) and one high (b) activity
region correspond to high and low cell densities in a 40-fold magnification.
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gained. In addition, flow cytometry confirmed that the
radioimmunoconjugate retained the Fab's biological properties.
The radiochemical purity of [177Lu]Lu-DTPA conjugated 6A10 Fab in
human plasmawas N90% after 72 h.Working with similar antibodies or
Fabs, chelated with DTPA or DOTA, and radiolabeled with 177Lu, differ-
ent groups reported comparable results to ours [32,33,39,40]. Therefore,
the stability of our tested [177Lu]Lu-DTPA-6A10 Fab was found to be
sufficient.
Autoradiography and HE-staining experiments on glioma xenograft
slices presented a correlation between uptake and cell density. Areas
with a high cell density showed a higher uptake while low cell density
resulted in lower uptake. This appears reasonable, since a higher num-
ber of cells correlates with more CA XII to bind the radiolabelled Fab.
Systemic distribution and uptake tendency of the radiolabelled Fab
was investigated by biodistribution studies. The verified activity accu-
mulation in the tumor is comparable to the results other groups pre-
sented in previous studies, for example with HER2 and CD20 Fabs
[41,42]. In contrast to a whole antibody, the systemic tumor uptake of
a Fab fragment is known to be lower and not as long-lasting [43], mainly
because of its monovalent binding site and faster digestion [44–47].
Comparing the uptake in tumor, blood and muscle at 48 h (1.8 ± 0.5%
ID/g, 0.1 ± 0.01%ID/g and 0.1 ± 0.02%ID/g respectively), the tumor
showed a significant activity level in comparison to the blood. Simulta-
neously, no retention inmuscle tissue occurred. These results, in combi-
nation with the reduced uptake detected in first autoradiographic
blockage experiments on tumor slices, indicates the specific binding
ability of the conjugate on the tumor. The rapid clearance in blood and
muscle together with the tumor uptake value implies a good tumor to
background ratio, which is favorable for tumor imaging [42]. Further-
more, the significant low brain uptake indicates, that the conjugate
does not cross the blood brain barrier. Similar to the blood, organs
such as heart, lung, stomach and intestines showed rapid activity reduc-
tion. As expected, liver and kidney show high accumulation values
around 3.1 ± 1.1%ID/g and 55.6 ± 13.0%ID/g, respectively.
Renal biomolecule metabolism is highly dependent on molecular
size and properties [45,48]. Large proteins, such as antibodies, do not
enter the glomerulus ultrafiltration system, which results in longer
blood retention times [45,46]. Molecules below ~65 kDa are cleared
through the kidney, and undergo ultrafiltration, lysosome metabolism
and tubulus reabsorption processes [45,46,48]. According to Duncan
et al. and Behr et al. [49,50], lysosomes catabolize the protein-chelate-
conjugates into metal chelate fragments. Those fragments can hardly
cross the lysosome membrane and remain in the lysosomes for a long
time. Those findings are confirmed by the results Mendler et al. [41]
reported, as they found a correlation between the radiolabeling chemis-
try and the kidney uptake. Their comparison of 124I-iodinated Fab-PAS
and 89Zr-labelled Fab-PAS via chelator conjugation revealed a
significant high kidney accumulation up to 88%ID/g (24 h) of the
metal chelate, whereas the iodinated protein only reached a value of
0.4%ID/g.
To summarize these facts, the long kidney retention time of Fabs
labelled with radiometals can be attributed to their specific renal
metabolism, consisting of glomerulus ultrafiltration, tubular absorption,
degradation and retention through lysosomes and further reabsorption
processes. However, the future therapy aim is the local application of
the radioconjugate into the brain. In order to protect sensitive organs,
such as the kidney, leakage of the conjugate into the blood system
should be avoided. To test the leak-tightness of the resection cavity
and the Ommaya reservoir system, a small amount of the
radioconjugate can be injected prior to the therapy and a whole body
scintigram can confirm that the activity remains in the brain [9].
Additionally, the apparent inability of the conjugate to cross the BBB
can be regarded as beneficial, since this may avoid systemic distribution
of the drug resulting in minimization of radioactive exposure to
non-target organs. Further reduction of organ exposure during patient
treatment can be achieved by fractionated RIT, where the activity is
applied in several fractions to maximise the exposure time on the
glioma cells [9,51]. Furthermore, in case of conjugate leakage into the
Fig. 6. Autoradiographs of unblocked (a) and blocked (b) tumor slices. CA XII blockade revealed an uptake reduction of 49% in comparison to the unblocked tumor slice.
Fig. 7. Planar scintigraphy of 5 mice (M1–M5) 4 h p.i. Tumor localizations at the right shoulders are illustrated by the white arrows.
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blood system, several techniques to reduce tubular reabsorption, for
example inhibiting the tubular reabsorption by injecting a lysine
solution, have been reported [45,48]. The kidneys are reported to
express CA XII as well [52]. An intrinsic effect of the biomolecule can
be neglected, as the amount of Fab entering the blood system is
considered to be rather small, even in case of 10% leakage. Nevertheless,
performing a leakage test is even more important.
Biodistribution results were confirmed by preliminary planar
scintigraphy images. As discussed, kidneys showed a strong activity
accumulation in the planar images. The evaluation of the tumor-to-
contralateral ratios based on this images 4 h p.i. revealed a mean ratio
of 3.3 ± 0.3. Biodistribution data, on the other hand, revealed an
average tumor-to-contralateral ratio of 3.4 and 10 at 3 h p.i. and 6 h p.
i., respectively. The ratios evaluated with biodistribution and planar
images are comparable, especially in consideration of the decreasing
muscle-blood-activity over time and the limited spatial resolution, as
we used a human, which is not optimized for small animal imaging.
Further discrepancy between the calculations may be caused because
different mice were used for biodistribution and imaging experiments,
respectively.
In this study, tumor xenografts onmicewere used as a first proof for
binding of the radiolabelled 6A10 Fab to the glioma cells in vivo. A more
accurate and application-oriented research method would be provided
by examinations on an orthotopic animal model, since the planned
application will be local into the resection cavity in the brain. Neverthe-
less, realization of such a model is difficult, since this would include
tumor inoculation, tumor resection and radiochemotherapy prior to
the local application of the Fab. A corresponding suitable and preclinical
model does not yet exist for technical and regulatory reasons.
Further investigations in this topic will be focused on establishing a
GMP compliant production routine as the next step towards future
clinical applications.
5. Conclusions
The 6A10 Fab can be successfully conjugated with p-SCN-Bn-CHX-A
″-DTPA and radiolabelledwith 177Lu. This conjugate is sufficiently stable
under physiological conditions, binds successfully to CA XII, shows
significant tumor accumulation in a xenografted model after systemic
application and does not cross the blood-brain barrier. As a next step,
the establishment of an orthotopic glioma model is planned, to
corroborate our first results with special emphasis on tumor
accumulation and biodistribution.
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Fully Automated Production and Characterization of 64Cu
and Proof-of-Principle Small-Animal PET Imaging Using
64Cu-Labelled CA XII Targeting 6A10 Fab
Luise Fiedler,*[a] Markus Kellner,[b] Rosel Oos,[a] Guido Bçning,[a] Sibylle Ziegler,[a]
Peter Bartenstein,[a] Reinhard Zeidler,[b, c] Franz Josef Gildehaus,[a] and Simon Lindner*[a]
Introduction
As a powerful noninvasive imaging tool, positron emission to-
mography (PET) offers the possibility to visualize and monitor
biochemical and physiological functions as well as pathophy-
siological processes in vivo. To investigate rapid molecular dis-
tribution and accumulation characteristics, short-lived PET radi-
onuclides such as 11C (t1/2 = 20.4 min),
68Ga (t1/2 = 67.7 min) and
18F (t1/2 = 109.8 min) are commonly used.
[1–6] For instance,
[18F]FDG is a radiolabelled glucose molecule with rapid tumor
uptake characteristics and is one of the most prominent tracers
in the field of tumor imaging.[6, 7] Radionuclides with longer
half-lives such as 89Zr (t1/2 = 3.27 days) and
124I (t1/2 = 4.18 days),
are needed to image molecules with slower biochemical pro-
cesses and longer blood availability, such as antibodies.[8, 9]
Fragment antigen binding (Fab) fragments of antibodies, on
the other hand, have shorter bioavailability than full-length an-
tibodies, but much longer availability than small molecules,
such as glucose.[10–12] Radiolabelling such molecules with an in-
termediate half-life PET nuclide such as 64Cu (t1/2 = 12.7 h)
might therefore be promising. Furthermore, in addition to b+
and electron capture, 64Cu decay includes a significant b! com-
ponent (probability of 39.0"3 %).[13–15] Thus, the combination
of PET imaging with radiotherapy may be feasible, which is not
the case for 124I and 89Zr.[16–19]
Various kinds of molecules have been radiolabelled with
64Cu to investigate possible PET applications against a wide
range of diseases. One of the most common 64Cu-radiolabel-
ling methods is based on the use of a chelating agent to bind
the radioactive metal to the carrier molecule. Copper offers
well-established coordination chemistry which allows the use
of various chelators, such as DiamSar, NOTA, NODA-GA, PCTA
and their derivatives.[20, 21] Using chelator-conjugated antibod-
ies, 64Cu has been investigated in studies against pancreatic
cancer,[22] malignant lymphoma,[23] breast cancer,[24] and car-
bonic anhydrase (CA) IX expressing malignant tissue.[25] Anti-
body fragments (Fab and F(ab)2), also radiolabelled with
64Cu
via chelators, have been used in studies against ovarian
cancer,[26] breast cancer,[26, 27] and head and neck cancer.[28] Che-
lator molecules are further used to bind 64Cu to peptides, such
as RGD2-BBN heterotrimers against prostate cancer,
[29] and RGD
peptides against gliomas.[30] Chelator conjugating is even used
to radiolabel nanoparticles[31] and liposomes for breast cancer
diagnosis.[32] Copper-labelled complexing agents such as ATSM
or some bifunctional chelators have been further investigated
for use as diagnostics against hypoxia[33, 34] and Alzheimer’s dis-
ease,[35, 36] respectively.
Because chelators might change the pharmacokinetics and
binding ability of the conjugated molecule, the development
of chelator-free radiolabelling strategies is interesting. Using
nanoparticles based on gallic acid is one way to ensure chela-
tor-free radiolabelling, as the phenol groups interact strongly
with 64Cu.[37–39] Promising preclinical results of such approaches
have already been reported for studies against breast
cancer.[37, 38, 40] A further method to generate 64Cu-labelled struc-
64Cu is a cyclotron-produced radionuclide which offers, thanks
to its characteristic decay scheme, the possibility of combining
positron emission tomography (PET) investigations with radio-
therapy. We evaluated the Alceo system from Comecer SpA to
automatically produce 64Cu for radiolabelling purposes. We es-
tablished a 64Cu production routine with high yields and radio-
nuclide purity in combination with excellent operator radiation
protection. The carbonic anhydrase XII targeting 6A10 anti-
body Fab fragment was successfully radiolabelled with the pro-
duced 64Cu, and proof-of-principle small-animal PET experi-
ments on mice bearing glioma xenografts were performed. We
obtained a high tumor-to-contralateral muscle ratio, which en-
courages further in vivo investigations of the radioconjugate
regarding a possible application in diagnostic tumor imaging.
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tures is the use of radioactively doped starting material. As a
result, the radionuclide is embedded in the structure’s matrix,
as is the case for 64Cu-containing quantum dots, which are
under investigation for PET studies against gliomas.[41] Further-
more, structures like liposomes or micelles or even nanoparti-
cles can be used to encapsulate 64Cu-linked molecules which
might be useful to influence the molecule’s properties, for in-
stance, by increasing its hydrophilic properties.[39, 42] Due to this
wide range of promising applications for 64Cu, establishing a
production routine was further investigated in this study.
The cyclotron production of 64Cu via the 64Ni(p,n)64Cu reac-
tion has already been extensively investigated.[18, 19, 43] Several
research groups have established 64Cu production routines,
but mostly with individual custom-made, semi-automated pro-
cesses and equipment.[19, 44–47] Comecer SpA (Castel Bolognese,
Italy) developed an automatic setup, the so-called Alceo mod-
ules, to cover all processes regarding 64Cu production: electro-
chemical fabrication of the 64Ni target, cyclotron irradiation
and subsequent dissolution of the target, purification and final
preparation of the 64Cu product. All procedures can be per-
formed automatically without manual intervention, which en-
sures a high level of radiation protection for the operator. Mat-
arrese et al.[48] first introduced these modules, but used an indi-
vidual modified electrochemical cell. Our study is focused on
establishing a 64Cu routine production with the unmodified,
commercially available first-generation Alceo modules
(Figure 1) to perform preliminary PET imaging experiments.
The Alceo setup consists of the PRF (purification), the EDS
(electrodeposition/dissolution/transfer/storage) and the PTS (ir-
radiation/cooling) unit. To prepare the irradiation target, a 64Ni
solution circulates between the PRF and the electrochemical
cell in the EDS module. A main part of the electrochemical cell
is the so-called shuttle, which is a cylindrical hollow aluminum
device (height 35 mm, diameter 28 mm) with an integrated
platinum beaker. The ground area of this beaker is used as
backing for 64Ni electrodeposition. The lid of the electrochemi-
cal cell equipped with a platinum rod anode is closed above
the shuttle, which is placed on the gold-foiled brass cathode
beneath (Figure 2). Through a tube system, the shuttle is auto-
matically transferred to the PTS module, which is installed on
the in-house biomedical cyclotron and positioned in the beam-
line. Cooling of the shuttle backing and the nickel target
during irradiation is maintained using water and helium, re-
spectively.
The shuttle is delivered back to the EDS unit, and the irradi-
ated target is dissolved using the circularly arranged capillaries
between EDS and PRF. The target solution is purified by anion-
exchange chromatography[49] in the PRF. Recovered nickel can
be processed for repeated use as target material. The purified
64CuCl2 is sent to the TADDEO module (Comecer SpA) for
volume reduction (Figure 1 D).
The produced 64Cu was further characterized, used for radio-
labelling experiments, and the initial in vivo small-animal PET
imaging experiments were performed. For this, the Fab frag-
ment of the new 6A10 antibody (6A10 Fab) was used, which
binds with high specificity to CA XII.[50, 51] CA XII is a membrane
enzyme that catalyzes the generation of bicarbonates for buf-
fering purposes in cells that are covering their high energy de-
Figure 1. Modular setup of the Alceo system: The shuttle is transported between the EDS (A) and PTS (B) via a delivery pipe, EDS (A) and PRF (C) are connect-
ed by capillaries to enable the circulating fluid transport, and the final product is transferred from the PRF (C) through capillaries to the TADDEO module (D)
for final processing.
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mands by extensive anaerobic glycolysis.[50, 51] This enzyme is
expressed on various aggressively growing cancer cells,[52, 53]
such as renal carcinoma,[54–56] breast cancer,[57] ovarian
tumors,[58] and gliomas.[59] The 6A10 Fab has already been ra-
diolabelled with 177Lu and investigated for potential use as a
radiotherapy agent against glioma recurrence.[60] Further appli-
cations as a diagnostic tracer, radiolabelled with the PET nu-
clide 64Cu, is now considered to extend the use of this biomol-
ecule for tumor imaging.
Next to the establishment of an automated Cu production
with the Alceo setup, the aim of our study was to evaluate the
possibility of generating a 64Cu-labelled 6A10 Fab for proof-of-
principle PET experiments on mice bearing CA XII expressing
tumor xenografts.
Results and Discussion
Target preparation and irradiation
Enriched 64Ni was electrochemically deposited from an aque-
ous Ni(SO4)2 solution in a dynamic cycle. In comparison with
other research groups who used static electrochemical cells for
nickel target deposition,[19, 44, 45, 61, 62] the Alceo setup uses the
dynamic deposition method, in which the shuttle is part of the
electrochemical cell, and the nickel is deposited directly on the
shuttle’s platinum beaker. This method prevents the accumula-
tion of hydrogen at the cathode, which has been reported to
disrupt the deposition process when using static setups.[48, 63]
To successfully produce a nickel target for irradiation, the flow
of the electrolyte solution must be adjusted very accurately to
1.2–1.4 mL min!1. In this flow range, typical electrodeposition
yields of up to 96 % were reached. When using flows higher
than 1.4 mL min!1, the yields radically decreased. Recovery and
re-electrodeposition of already irradiated nickel material was
accomplished with yields of up to 90 %. The generated deposit
(Figure 3 B) was conically shaped, with a diameter of 7 mm, in-
creasing thickness in the middle, and a rough, pitted surface.
This appearance was most likely caused by the geometry of
the electrochemical cell, as the anode is a platinum rod, and
the cathode is a round-shaped platinum surface. The anode is
positioned centrically above the cathode, which results in an
increased deposition rate in the middle. Because the target
gets very pointy and brittle at the tip if too much material is
deposited, nickel amounts above 85 mg are not usable for fur-
ther irradiation experiments.
A paper burn test was performed to determine the beam
position on the shuttle required to effectively irradiate the
nickel target. For that reason, a shuttle was equipped with a
paper and irradiated for a short time. In Figure 3, panels A and
B show the beam position on the burned paper and a repre-
sentative nickel target. The cross in both figures indicates the
center of the shuttle, where both 64Ni and proton beam are lo-
cated. This confirmed that the beam successfully hits the
target during irradiation.
The beam energy was varied through the installation of alu-
minum foils of different thicknesses in the beam line. Accord-
ing to the 64Ni(p,n)64Cu cross-section, the highest nuclear reac-
tion yield can be expected at 11 MeV proton beam energy.[64, 65]
However, we observed an overall decreasing activity yield in
correlation with the decreasing beam voltage. Proton energies
of 11, 13.2 and 14.5 MeV resulted in average yields of 0.25"
0.15, 0.44"0.14 and 0.72"0.20 MBq/mA/h/mgNi, respectively.
This can be explained by a decreased proton flux hitting the
target with increasing degrader foil thickness. Table 1 contains
a summary of 16 representative 64Cu production runs with the
corresponding amounts of used 64Ni, irradiation parameter,
and radioactive yields.
In comparing batches with similar amounts of nickel (B1 and
B3, B5 and B7, B8 and B9), the yielded activity at the end of
bombardment (EOB) was improved by elevating the beam cur-
rent and duration. Increasing the amount of nickel target but
using constant beam parameters (B12 and B13, B10 and B11,
B16 and B15) also resulted in improved yields. Higher nickel
amounts cannot be deposited, and longer irradiation times or
higher currents are limited due to technical restrictions. Never-
theless, significant yield deviation was observed, even though
similar nickel amounts and equal beam parameters were used
(B13 and B15, B12 and B14). These variances are most likely
due to an uneven quality of the nickel target caused by an un-
reliable electrodeposition process. The Alceo setup is charac-
terized by a very long capillary circuit, which is used in differ-
ent steps of the 64Cu production. This can cause ionic cross-
contaminations, which might disturb the electrochemistry pro-
cess and can lead to irregular nickel deposition. Additionally,
the pre-installed membrane pump is not able to establish a
Figure 2. Electrochemical cell of the EDS module: A) open cell with marked
positions of anode and cathode; B) shuttle in position for electrodeposition
and dissolution with closed electrochemical cell.
Figure 3. Result of the paper burn test shows the position of the beam on
the shuttle (A), while B shows a 64Ni-plating on the shuttle’s platinum
beaker.
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constant flow of the solution. Thus, to produce a reliable 64Ni
target and consequently a predictable irradiation yield, modifi-
cation of the pump and the electrochemical cycle is highly rec-
ommended to increase the irradiation output.
Characterization
The irradiated target was dissolved in HCl, and the 64Cu was
separated from nickel target material and irradiation by-prod-
ucts using anion-exchange chromatography. With a final
volume of 9 mL, the 64CuCl2 was not suitable for radiolabelling
purposes, so the product was evaporated to dryness and re-
dissolved in HCl (400 mL; 0.1 m) using the TADDEO module. The
final 64CuCl2 had an approximate pH 0.4 at the end of prepara-
tion (EOP). A half-life of 12.7!0.5 h was confirmed via dose
calibrator measurement. The identity of the produced 64Cu was
verified by gamma spectroscopy (Figure 4). Next to the
511 keV peak, the characteristic g-peak of 64Cu at 1345 keV was
identified. The radionuclide purity was calculated to be >99 %
(EOP).
When irradiating enriched 64Ni with protons, the formation
of radionuclide by-products has been reported.[19, 45, 46, 66] Due to
the limited purity of enriched 64Ni (<99.32 % purity), some im-
purities are expectable. To eliminate short-lived copper iso-
topes, anion-exchange purification of the product was per-
formed after an overnight decay (~12 h), which resulted in ex-
cellent radionuclide purity at the end of preparation. All purifi-
cation fractions were analyzed by gamma spectroscopy, and
the overall contents of radionuclides were quantified. Table 2
lists the resulting contents of n = 11 separations in atomic per-
cent (At %), decay corrected to EOB.
The cobalt isotopes 55Co, 57Co and 61Co were identified with
contents of 0.03!0.10, 0.004!0.014 and 1.4!3.4 At %, re-
spectively. The amount of 64Cu was determined to be 98.5!
3.4 At %. Radionuclides with short half-lives, such as 60–62Cu,
were not detected in the examined sample. This supports the
implementation of a 12 h time interval between EOB and EOP
for elimination of any short-lived isotopes.
The molar activity (Am) of the produced
64CuCl2 was deter-
mined by titration with the chelator 1,4,8,11-tetraazacyclotetra-
decane-1,4,8,11-tetraacetic acid (TETA).[19] To do so, aliquots of
TETA at different concentrations were radiolabelled with 64Cu,
and the radioactive yield was determined with radio-TLC. Due
to an equimolar reaction between metal and chelator, the
molar activity (Bq mol"1) can be calculated. Non-radioactive
metallic ion contaminations would compete with the 64Cu to
complex with TETA, so this method determines the effective
molar activity (eff. Am) of the entire
64CuCl2 product rather than
the theoretical activity per mole 64Cu. To determine the theo-
retical Am, a direct method such as mass spectrometry tech-
niques is recommendable.[44, 45] Because the eff. Am is decisive
for radiolabelling purposes, we focused on the TETA titration
method in this study.
Improving the eff. Am was accomplished by changing the
solvent for cleaning of all the module reservoirs and capillaries
prior to 64Cu production. We first used only Tracepur! water (#
1.0 ppb Cu; #1.0 ppb Fe) and switched during development
to a two-step method, which includes pre-cleaning with Trace-
Table 1. List of 16 64Cu production runs with the sample IDs, the corre-
sponding amounts of 64Ni, beam parameters and resulting yields, decay
corrected to the end of bombardment (EOB).
ID 64Ni [mg] Beam parameters Yield EOB
[MeV] [mA*h] [MBq] [MBq/mA/h/mgNi]
B1 46.9 14.5 18 660
0.72!0.20
B2 58.0 14.5 60 2362
B3 50.6 14.5 85 4443
B4 41.0 14.5 100 3604
B5 84.5 14.5 57 3100
B6 82.0 14.5 75 2509
B7 83.5 14.5 100 5389
B8 85.3 11.0 100 941
0.25!0.15B9 78.5 11.0 150 1702
B10 24.0 11.0 150 1532
B11 39.7 11.0 150 2005
B12 23.0 13.2 150 1826
0.44!0.14
B13 42.0 13.2 150 2394
B14 26.0 13.2 150 976
B15 42.6 13.2 150 3969
B16 35.0 13.2 150 2118
Figure 4. Exemplary gamma spectrum of the produced 64Cu with the annihi-
lation peak (511 keV) and the copper-specific g-peak at 1345 keV.
Table 2. Average amounts of irradiation products in atomic percent
(At %) at EOB (n = 11). Nuclides that were not detected are declared as
n.d. (not detectable). Gamma spectrometry measurements were per-
formed 10–12 h post-EOB.
Element Isotope Half-life At % @ EOB
Cobalt
55 17.5 h 0.03!0.10
57 271.8 d 0.004!0.014
61 1.7 h 1.4!3.4
Copper
60 23.7 min n.d.
61 3.4 h n.d.
62 9.7 min n.d.
64 12.7 h 98.5!3.4
ChemMedChem 2018, 13, 1 – 9 www.chemmedchem.org " 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim4&
!! These are not the final page numbers!
Full Papers
Original Publications   
 42 
pur! water and final rinsing with Ultrapur! water (!0.1 ppb
Cu; !0.3 ppb Fe). To monitor the rinsing efficiency, diluted ali-
quots of decayed 64CuCl2 batches were analyzed with ICP-OES
for metallic contaminations of Co, Cr, Mn, Ni, Zn, Cu and Fe.
Metal contents of significance were found for Cu, Fe, Ni and
Zn, and are plotted in Figure 5 in correlation with the deter-
mined effective molar activity.
B6 and B7 show the results of a system that was rinsed with
Tracepur! water using a small anion-exchange column (3 g
resin) for separation. In both batches, remarkably high
amounts of Fe and Zn were detected. The amount of resin was
increased up to 9 g in B10 and B13, while rinsing was still car-
ried out with Tracepur! water, resulting in decreased Fe and
Zn contents.
Finally, cleaning of all production-relevant lines and cycles
was performed with Ultrapur! water, leading to a decreased
content of Fe in B15 and B16. Simultaneously, a significant im-
provement of the eff. Am was reached using high-purity water
for cleaning (120.5"17.7 GBq mmol#1 in B15 and B16 versus
34.5"3.1 GBq mmol#1 in B6, B7, B10 and B13). Varying amounts
of Cu and Ni were detected over all batches.
The amount of determined nickel in the product does not
correlate with improvements made for purification and rinsing.
We therefore assume that the majority of the nickel originates
from the nickel target. Minor amounts of non-radioactive Ni
and Zn can be attributed to 64Cu decay, as it is characterized
by 39.0"3 % b# decay to 64Zn ground state, and 17.86"14 %
b+ and 42.6"5 % electron capture decay to 64Ni ground
state.[13–15] Co, Cr and Mn were not found in significant
amounts.
An optimized molar activity of 64Cu is an important prerequi-
site for imaging purposes. Using different technical setups,
processing methods and irradiation parameters, a wide range
of possible molar activities has been published. Table 3 shows
a comparison between the results presented in this study and
previously published molar activities of other groups. With up
to 133 GBq mmol#1, our method generates moderate values,
higher than those reported by Jeffery et al. ,[45] Matarrese
et al.[48] and Obata et al. ,[62] but lower than those achieved by
Avila-Rodriguez et al. ,[46] McCarthy et al. ,[19] Ohya et al.[67] and
Thieme et al.[44] Our results can best be compared with those
of Matarrese et al. ,[48] who also worked with the Alceo mod-
ules. They reported an effective molar activity of 81.4"
48.1 GBq mmol#1, which was moderately improved to maximum
133 GBq mmol#1 in this study.
Limitations of the Alceo modules
By using the first-generation Alceo modules, an automatic pro-
duction of 64Cu can be established. However, some improve-
ments might be recommended to further optimize the process
reproducibility and the molar activity of the 64Cu product. The
modules are equipped with very long capillary circuits for all
production steps, and the same lines are used for nickel elec-
trodeposition and dissolving prior and post-irradiation. This
might result in metal ion cross-contaminations, which must be
removed by extensive rinsing procedures. A better way to di-
minish problems associated with those cross-contaminations
would be to strictly separate the two cycles and to significantly
shorten the fluid pathways. Furthermore, a setup based on dis-
posable kits would even guarantee a production that is free of
any contamination.
An improved reproducibility regarding the electroplating
process can further be reached by installing a pump with a
more stable performance, as the pre-installed device shows un-
equal pump velocity over a long operating time.
The initially produced 64CuCl2 is so far available in 9 mL,
which results in a volume-concentration too low for radiolabel-
ling purposes. In this study, the TADDEO module had to be
used for volume reduction. With an integrated solution, for ex-
ample, a pre-installed heating device for evaporation, the
Alceo setup would enable a convenient production outcome
of labelling-suitable 64Cu.
Radiolabelling and PET imaging
The 6A10 Fab, conjugated with p-NCS-benzyl-NODA-GA, was
radiolabelled with 64Cu and purified with a nap-5 column (GE
Healthcare, Munich, Germany). The radiochemical purity of the
product was determined by radio-TLC to be >93 %. In five syn-
Figure 5. A representative comparison of the contents of non-radioactive
metals [mg mL#1] and the corresponding molar activity (Am) [GBq mmol
#1] .
Table 3. Comparison of the molar activities reported in previous studies
and in this study, in correlation with the measurement methods used.
Authors Molar activity
[GBq/mmol]
Measurement method
Ohya et al.[67] 1170"1170 ICP-MS
Avila-Rodriguez et al.[46] 696"122 Titration with TETA
Thieme et al.[44] 1072"420 ICP-MS
McCarthy et al.[19] Up to 733 Titration with TETA
Current study Up to 133 Titration with TETA
Obata et al.[62] 118"67 Titration & HPLC with ATSM
Jeffery et al.[45] 89"37 ICP-MS
Matarrese et al.[48] 81"48 HPLC
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thesis runs, we reached a final specific activity of the radiola-
belled compound of 208.6!49.7 MBq mg"1. A female SCID
mouse, bearing a glioma xenograft on the right shoulder (~
370 mm2) was injected with 14.7 MBq of the conjugate via a
tail vein catheter and scanned by small-animal PET. The image
is shown in Figure 6. The tumor-to-contralateral muscle ratio
was calculated to be 12.
The image also shows activity accumulation in organs such
as kidney, liver, bladder, spleen and intestines. According to
our previous work,[60] this accumulation pattern can be expect-
ed, as the metabolism of proteins with molecular weight simi-
lar to a Fab fragment (~55 kDa) is dominated by kidney and
liver. The calculated tumor-to-contralateral muscle ratio of 12 is
notably high for a systemically applied Fab fragment, as Fabs
undergo rapid degradation processes and are therefore much
more short-lived in the blood than full-length antibodies.[10–12]
This encourages further studies regarding the in vivo behavior
of this 64Cu-labelled compound for diagnostic imaging of CA
XII expressing tumors.
Conclusions
The Comecer Alceo modules offer the possibility to produce
64Cu in good radioactive yields, high radiochemical purity, and
good effective molar activity for radiolabelling of biomolecules.
Due to the high grade of automatization an excellent radiation
protection for the operator can be expected. Labelling of the
6A10 antibody Fab fragment and proof-of-principle small-
animal PET experiments were accomplished and showed prom-
ising imaging results.
Further studies are considered to investigate the in vitro and
in vivo characteristics of the 64Cu-labelled 6A10 Fab in regard
to a possible diagnostic application against CA XII expressing
tumors.
Experimental Section
Unless otherwise mentioned, all chemicals and expendable items
were purchased from Sigma–Aldrich (Taufkirchen, Germany), Carl
Roth (Karlsruhe, Germany), or Eppendorf (Hamburg, Germany). All
glassware and capillaries were routinely cleaned prior to produc-
tion with HNO3 (2 m), rinsed with water and dried with nitrogen.
During the evaluation process in this work, the purity grade of the
used water was continuously refined.
Target preparation : The electrolyte bath was prepared according
to McCarthy et al.[19] The enriched 64Ni (20–90 mg, <99.32 % purity,
Chemotrade Chemiehandelsgesellschaft mbH, D!sseldorf, Germa-
ny) was dissolved in HNO3 (2 mL, 6 m), evaporated to dryness, re-
dissolved in H2SO4 (300 mL, concentrated), diluted with H2O (2 mL),
evaporated to near dryness and diluted with H2O (5 mL). The solu-
tion was adjusted to pH 9 with NH3, and (NH4)2SO4 (0.3 mg) and
H2O (2 mL) were added to a final volume of 8–9 mL. Nickel deposi-
tion on the shuttle occurred under constant circulation of the solu-
tion with 1.2–1.4 mL min"1, at 2.6 V and a current between 0–
30 mA, depending on the amount of nickel remaining in the solu-
tion. After 20–24 h, the solution turned colorless, which indicates
the complete nickel deposition. By weighing the shuttle before
and after electrodeposition, the amount of deposited nickel was
determined. The circulation cycle and the plated nickel was rinsed
with H2O and dried with nitrogen.
Irradiation : For irradiation a PETtrace 800 series cyclotron from GE
Healthcare (Uppsala, Sweden) was used. Confirmation of the cor-
rect shuttle position in the beam line was obtained by a paper
burn test. For that purpose, a shuttle was equipped with a paper
and irradiated for 16 s with 5 mA at 13.2 MeV. Several irradiation
conditions were tested. The initial 16 MeV beam was degraded by
different aluminum foils. Using 320, 500 and 820 mm foils resulted
in beam voltages of 14.5, 13.2 and 11 MeV, respectively.[68] The irra-
diation took up to 5 h and current values between 20–30 mA were
tested. The temperature range of cooling water and helium was
set to be at ~20!5 8C.
Purification and preparation of 64Cu : After an overnight decay,
the irradiated target was dissolved with HCl (5 mL, 6 m) at 90 8C
shuttle temperature over 1 h. A BioRad Econo-Column with AG1-
X8 chloride form resin (200–400 mesh, BioRad, Hercules, CA, USA)
was loaded with the solution. In three steps, unreacted nickel, co-
produced cobalt and copper product were eluted with 6 m HCl
(30 mL), 4 m HCl (15 mL) and 0.1 m HCl (9 mL), respectively. The
64Cu fraction was delivered to the TADDEO module and evaporated
to dryness at 160 8C in 1 h under a constant nitrogen flow, and fi-
nally re-dissolved in 400 mL. To recover the decayed 64Ni, the first
fraction was loaded on the AG1-X8 resin, eluted with 6 m HCl
(30 mL), evaporated to dryness, re-dissolved in H2O (20 mL), evapo-
rated to dryness, re-dissolved in ethanol (15 mL) and evaporated
to dryness. The residue was retreated with HNO3 (2 mL, 6 m) and
further processed as previously explained, to prepare the electro-
chemical 64Ni solution.
Characterization : The pH of the copper fraction was determined
with a pH meter by Mettler Toledo (Greifensee, Switzerland). All
three purification fractions were analyzed by gamma spectroscopy
(GC2020-CP5SL, Mirion Technologies (former Canberra) GmbH, R!s-
selsheim, Germany) with the Gamma Analysis S501 software pack-
age), to calculate the overall radionuclide composition of the pro-
Figure 6. PET image of a mouse scanned 4 h after injection of 14.7 MBq of
the radioconjugate. The tumor xenograft on the right shoulder is indicated
with a white arrow.
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duction run and to determine the 64Cu purity. Using an ISOMED
2010 dose calibrator (MED Nuklear-Medizintechnik Dresden GmbH,
Dresden, Germany), final product activity and half-life were verified.
The specific activity of 64Cu was determined via titration with TETA
(1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid, from
Macrocylics, Dallas, TX, USA), as presented by McCarthy et al.[19] A
copper stock solution in NH4OAc (0.1 m, pH 5.5) with a concentra-
tion of 10 MBq per 30 mL was prepared; 0.03–0.2 mg of TETA and
10 MBq copper stock solution were diluted in NH4OAc (300 mL,
0.1 m, pH 5.5) and incubated for 30 min at 37 8C. Radio-TLC was
performed on ITLC-SA strips (Agilent, Waldbronn, Germany) with
NaCl (0.9 %) as mobile phase (Rf(TETA) = 0.8–0.9; Rf(
64Cu) = 0.0). ICP-
OES analysis was performed on decayed 64Cu aliquots at the ana-
lytical division of the Faculty for Chemistry and Pharmacy, LMU
Munich, to determine non-radioactive metallic impurities (Co, Cr,
Cu, Fe, Mn, Ni, Zn).
Labelling : The 6A10 Fab was conjugated with p-NCS-benzyl-
NODA-GA (2,2’-(7-(1-carboxy-(4-(4-isothiocyanatobenzyl)amino)-4-
oxobutyl)-1,4,7-triazacyclononane-1,4-diyl)diacetic acid from CheM-
atech (Dijon, France)) in phosphate buffer (400 mL reaction volume,
0.1 m, pH 8.5) for 1 h at 37 8C. Not complexed chelator was re-
moved using nap-5 columns (GE Healthcare, Munich, Germany).
The conjugate was labelled with 64CuCl2 in NH4OAc (500–600 mL re-
action volume, 0.1 m, pH 5.5) at 37 8C for 20 min followed by a
nap-5 column purification. Radio-TLC on ITLC-SA strips (15–95 mm)
in citric buffer (pH 4.5) was used for quality control (Rf(Fab) = 0.0–
0.1; Rf(NODA-GA) = 0.1–0.3; Rf (free
64Cu)= 0.1–1.0).
PET imaging : The glioma cell line U87MG (American Type Culture
Collection) was cultivated in Gibco MEM media by Thermo Fischer
Scientific (Munich, Germany), supplemented with fetal bovine
serum and l-glutamine (Biochrom Berlin, Germany) and kept at
5 % CO2 and 37 8C in a CB150 incubator by Binder (Tuttlingen, Ger-
many). 5 ! 106 U87MG cells were subcutaneously injected into the
right shoulder of a female SCID mouse (6–8 weeks, 20–25 g).
14.7 MBq was injected through a tail vein catheter after a tumor
growth time of 12 days. Under constant anesthesia (Isoflurane Vet.
Med. Vapor, Dr"gerwerk, L#beck) the mouse was scanned 4 h post-
injection for 70 min (60 min emission and 10 min transmission) on
an Inveon P120 mPET scanner (Siemens, Munich, Germany; Inveon
acquisition workplace, Siemens Medical Solutions, Knoxville, USA).
PET images were analyzed with the Inveon Research Workplace
software. Region-of-interest (ROI) analysis was performed using a
tumor ROI based on 40 % threshold (239 mL) and a background ROI
(ellipsoid, 100 mL) in the contralateral thigh muscle. Average ROI
counts were calculated. All animal experiments were performed in
accordance to the current German animal protections laws and
protocols of the local authorities.
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